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Systemic sclerosis (SSc), the most lethal of rheumatologic conditions, is the cause of death in >50% of SSc cases, led by pulmonary
ﬁbrosis followed by pulmonary hypertension and then scleroderma renal crisis (SRC). Multiple other preventable and treatable
SSc-related vascular, cardiac, gastrointestinal, nutritional and
musculoskeletal complications can lead to disability and death.
Vascular injury with subsequent inﬂammation transforming to
irreversible ﬁbrosis and permanent damage characterizes SSc.
Organ involvement is often present early in the disease course of
SSc, but requires careful history-taking and vigilance in screening
to detect. Inﬂammation is potentially reversible provided that
treatment intensity quells inﬂammation and other immune
mechanisms. In any SSc phenotype, opportunities for early treatment are prone to be under-utilized, especially in slowly progressive phenotypes that, in contrast to severe progressive ILD,
indolently accrue irreversible organ damage resulting in laterstage life-limiting complications such as pulmonary hypertension, cardiac involvement, and malnutrition.
A single SSc patient visit often requires much more physician and
staff time, organization, vigilance, and direct management for
multiple organ systems compared to other rheumatic or pulmonary diseases. Efﬁciency and efﬁcacy of comprehensive SSc care
enlists trending of symptoms and bio-data. Financial sustainability
of SSc care beneﬁts from understanding insurance reimbursement
and health system allocation policies for complex patients. Sharing
care between recognised SSc centers and local cardiology/pulmonary/rheumatology/gastroenterology colleagues may prevent
complications and poor outcomes, while providing support to local
specialists.
As scleroderma specialists, we offer a practical framework with
tools to facilitate an optimal, comprehensive and sustainable
approach to SSc care. Improved health outcomes in SSc relies upon
recogntion, management and, to the extent possible, prevention of
SSc and treatment-related complications.
© 2021 Elsevier Ltd. All rights reserved.

Introduction
Systemic sclerosis (SSc), the most lethal of rheumatologic conditions, is the direct cause of death in
>50% of SSc cases, followed by pulmonary ﬁbrosis, pulmonary hypertension, and scleroderma renal
crisis (SRC). Multiple other preventable and treatable SSc-related vascular, cardiac, gastrointestinal,
nutritional, and musculoskeletal complications also lead to disability and death.
SSc is characterized by vascular injury and disrepair that incites systemic progressive inﬂammatory
transformation to ﬁbrosis at widely variable rates and intensities. Inﬂammation is a reversible
3
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phenomenon provided the intensity of treatment matches that of the inﬂammation. End-stage ﬁbrosis
is permanent and irreversible. Organ involvement is present early in the SSc disease course, requiring
ongoing screening and careful patient questioning to detect. Reduction of disability and mortality
hinges on the prevention of vascular and ﬁbrotic damage, which is directly dependent upon early
recognition of active disease, even in the indolent disease phenotypes, with initiation of appropriate
treatment to prevent ﬁbrotic transformation.
Delayed diagnosis is common in autoimmune diseases and disproportionately frequent in those of
African and Hispanic descent, for whom these diseases tend to be more severe and deadly [1e6].
Importantly, slowly progressive phenotypes indolently accruing irreversible structural changes and
organ damage are less prone to receive treatment, resulting in end-stage SSc complications such as
pulmonary hypertension, cardiac involvement, and malnutrition. Diagnostic delays, misdiagnoses, and
complication oversights are likely underpinned by preferential reliance on laboratory data and a
clinical setting that is hurried which impair authentic empathetic listening, careful history-taking, and
physical exam performance.
Efﬁciency and efﬁcacy of SSc care that meets the health-related quality of life (HRQoL) and survival
needs of patients require trending of symptoms and over time; and also requires multiple streams of
management that are sustained by understanding visit reimbursement policies. A single SSc patient
visit commonly involves extensive chart review, investigation, coordination and direct management
for multiple organ systems, and exacting physician and staff time and effort beyond that of other
diseases. Sharing care between scleroderma centers and local specialists provides robust patientcentered management and patient skill-building for self-management of this complex disorder.
As scleroderma specialists, we offer an abbreviated reference manual and practical framework, that
we hope supports clinicians and patients, with informational summaries on symptoms, manifestations, and complications with tools and templates for screening, assessment, documentation, risk
stratiﬁcation, counselling, and anticipatory guidance, and discussions surrounding clinician
sustainability.
Pathologic drivers in SSc that impact treatment decisions
Inﬂammation-ﬁbrosis axis: from preventable to irreversible damage
Beyond the widely heterogeneous nature of SSc presentation, progression and potential organ
involvement, a major challenge impeding SSc care is the ability to distinguish between states of active
progressive disease and its subsequent ﬁbrotic damage. Inﬂammation-ﬁbrosis transformation is a
progressive process with an advancing front of potentially reversible inﬂammatory assault. Inﬂammatory tissue left untreated is damaged with increasing expanses of ﬁbrosis. Inﬂammation and ﬁbrosis
are often coexistent, but increasing ﬁbrotic expanse leads to worsening irreversible disability and,
possibly, death over time. Though currently difﬁcult to distinguish with certainty, even in the absence of
ESR or CRP elevation and regardless of coexistent ﬁbrosis or the rate of progression, the concern for any
degree of inﬂammation, i.e., progression, should prompt consideration to initiate systemic immunomodulatory therapy.
Symptoms and impairment burden dynamically relate to the extent of either inﬂammation, ﬁbrosis,
or a combination thereof (Fig. 1). Symptoms worsen with extent of involvement; but potential
symptom reduction or reversal with systemic treatment requires some degree of active tissue
inﬂammation to be present. For example, progressive ILD, can manifest by dropping forced vital capacity (FVC), dry inspiratory cough, and breathlessness that improves after systemic treatment [7e10].
Whereas, residual inactive ﬁbrotic damage resulting from prior inﬂammation is now unresponsive to
immunosuppression.
Circulation and mechanisms of disease
Vasculopathy, vascular injury with tissue hypoxia, and pathologic circulation interplay with and are
drivers of inﬂammation and ﬁbrosis. The earliest hallmark of SSc disease is vascular injury, dysfunction
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Fig. 1. SSc involved tissue, of which the lung is one example, experiences transition from healthy tissue to ﬁbrosis as inﬂammation is
incited and progressively extends within resident organs. Vascular injury with tissue hypoxia is an important factor to the development of tissue ﬁbrosis. Symptoms and disability can be transient in active inﬂammation with systemic treatment. Over time
untreated inﬂammation irreparably injures effected tissue, resulting in scarring and ﬁbrosis. Fibrosis is irreversible and results in
permanent organ-related disability. (Courtesy of LA Saketkoo, rights reserved).

and disrepair, without overt evidence of inﬂammatory inﬁltration i.e. not vasculitis [11,12]. Vascular
dysfunction and Raynaud's phenomenon (RP) symptoms predominantly predate non-RP symptoms by
several years. In the genetically predisposed host, vascular injury may incite immune system activation
through upregulation of adhesion cells and perivascular migration of immune cells, including macrophages, which may have a direct role in ﬁbroblast stimulation.
The presence of abnormal capillaroscopy predicts the development of connective tissue disease
(CTD) in patients with RP, and ANA positivity heightens that predictive power [13]. SSc nailfold
capillaroscopy patterns are well described reﬂecting the vasculature struggling against the pathologic
progression of the disease [14].(Fig. 2). The presence of abnormal nailfold capillaries contributes >20%
toward SSc classiﬁcation criteria [15] and predicts [16] the development of a CTD [17] and SSc
[13,16,18,19]; making capillaroscopy, with at least a handheld device, an essential assessment tool in
rheumatologic care (Fig. 3).
A normal nailfold bed demonstrates long thin hairpin loops resembling the abundance of wheat
ﬁelds. In the “early” and “active” SSc patterns, the capillaries dilate and giant loops occur, as well as
microhemorrhages, ballooning above the injured vessels. Later in the course of SSc, capillaries “dropout” leading to a rarefaction of the capillary network. Edematous “puffy ﬁngers” or diffuse inﬁltrative
ﬁbrosis sometimes make nailfold capillaries difﬁcult to visualize [19e25]. The “late” pattern is characterized by marked rarefaction and often reﬂects the vasculature's struggles to repair itself, albeit
ineffectively despite high levels of circulating pro-angiogenic factors, creating a network of thin,
matted vessels inefﬁcient for supporting healthy tissue. This can be seen also in GI and skin, i.e., GAVE
and telangiectasias.
Lethal vascular complications such as PH and cardiac involvement correlate with other circulatory
phenomena, e.g., digital ulcers (DU), telangiectasias [20,21], osseous vascular complications, e.g.,
radiographic calcinosis, and acro-osteolysis [22], and with inﬂammation-predominant complications,
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Fig. 2. Demonstration of ‘normal’ and various SSc patterns on nail fold video capillaroscopy. (Images courtesy of Vanessa Smith; University of Ghent, Belgium.)
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Fig. 3. Capillaroscopy is an essential rheumatologic service. An abnormal capillaroscopy satisﬁes >20% of SSc criteria and confers 96% predictive power for development of CTD, making it an
essential part of the rheumatologic exam. With any method, capillaries become increasingly easier to visualize with practice over time. (Courtesy of T Frech & LA Saketkoo, rights reserved). 1The
ophthalmoscope has lowest magniﬁcation but easily found in doctors’ ofﬁces. 2The dermatoscope is affordable, convenient and portable. 3The smartphone dermatoscope is affordable and easy to
use. 4. The stereomicroscope is costly, and cumbersome for transport. Images are comparable quality to that of dermatoscope. 5. The video capillaroscope is costly but produces high-quality
digital images enabling ﬁne measurements. The camera attaches to a laptop or other computer.
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e.g., arthritis and muscle involvement. These associations suggest a deep-rooted interplay between
systemic inﬂammation, autoimmunity, ﬁbrosis, and vasculopathy.
Systemic autoimmune, inﬂammatory drivers inﬂuencing SSc vascular complications is a major
current consideration in research and patient care [23e27]. SSc-speciﬁc autoantibodies help predict
the potential clinical course and phenotypes in SSc patients. However, only functional antibodies not
speciﬁc to SSc, such as the anti-endothelial cell antibody, demonstrate a direct pathogenic role,
although reports are conﬂicting [28,29]. Healing of non-friction DUs upon initiation of systemic
treatment, e.g., mycophenolate mofetil (MMF), and subsequent DU re-emergence upon immunosuppression discontinuation are anecdotally noted by SSc experts. Potential inﬂuence of immunosuppressants on improved outcomes in SSc-PH are increasingly being investigated [23e27].
Considerations that drive management in SSc
Goals of SSc management
Preventing death and permanent disability in SSc is accomplished with early and appropriate treatment.
SSc is an extensively complex disease often with delayed diagnosis. By the time patients receive expert
management, most will have permanently lost some degree of physical function and have diminished
well-being, eroding one's ability to sustain the crucial life areas and personal satisfactions of family,
intimate and social interactions including ﬁnancial solvency. Recent data suggest initiating early
treatment may prevent development or progression of complications such as ILD [30].
SSc is associated with signiﬁcant unemployment, worker absenteeism, and decreased worker
productivity [31]. Preventable SSc-related work impairment results in substantial economic burden
and diminished HRQoL [32] with loss of work, lost income, and loss of health insurance and healthcare.
Working closely with patients and their employers to attain appropriate modiﬁcations to their work
environment and situation may improve functioning and improve productivity [31e36].
Goals of SSc care are rooted in prevention and reversal of disease progression (including indolent
progression) and restoration of function and HRQoL due to diverse symptom burdens and therefore
include:






Early recognition of probable SSc and initiation of early appropriate systemic treatment for SSc
Early recognition, treatment and responsive observation of each SSc manifestation over time
Early recognition and prevention of complications related to SSc-manifestations and treatment
Engaging patients in preventive strategies via ongoing education and shared decision making
Early introduction of key specialists that preserve and augment function, health and HRQoL,
e.g. physiotherapists, occupational or respiratory therapists, dietician, cardiologist, gastroenterologist, pulmonologist, etc.
 Tight communication in care planning with key specialists and local care teams
 As much as is possible, restoration of baseline functioning for each manifestation
 As much as is possible, reduction of symptom burden for each manifestation

Risk awareness in SSc
The risk for and the actual rate of disease progression guide the level of systemic treatment
intended to quell inﬂammation and prevent further organ damage. They also identify patients with
rapidly progressive disease potentially beneﬁtting from more aggressive therapy such as hematopoietic stem cell transplantation (HSCT) before end-organ damage occurs. While there is no formal SSc
risk stratiﬁcation tool, certain factors put patients with SSc at even greater risk of death, disability and
rapidly progressive disease (Tables 1 and 2). Sensitizing clinicians to these risk factors heightens vigilance for treatable lethal and/or permanently disabling disease.
It should be clariﬁed that both limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc)
carry an increased risk of death. The terms diffuse and limited cutaneous are descriptors of skin
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Table 1
Risk factors for death, disability and rapidly progressive disease.
Risk Factor

Clinical measures

Indication of Rapidly Progressive SSc or Severe Disease

Diffuse skin involvement

Modiﬁed Rodnan total Skin
thickness Score (mRSS)
Palpable presence on exam
See measures for ILD, dcSSc,
renal crisis, and cardiac ﬁbrosis
PFT: spirometry
PFT: DLCO
HRCT: Extent of ground-glass
opacity and honeycombing
ﬁbrosis
Echocardiography

Increasing diffuse skin thickness, mRSS > 29

Tendon Friction Rub
Anti-topoisomerase I
Interstitial lung disease

Pulmonary arterial
hypertension (PAH)

Right heart catheterization

Cardiac Involvement

Digital ulcers, gangrene
Scleroderma renal crisis

WHO/NYHA Classiﬁcation
ECG
Echocardiography
Cardiac MRI
Nailfold capillaroscopy
Hypertension

Serum biomarkers
GAVE
Severe malabsorption

Polyarthritis
General health status
Comorbidities

Gastric bleeding
Anemia
Weight loss
Muscle atrophy
Stool frequency
Electrolytes
Albumin/Pre-albumin
HAQ-DI
DAS-28
Weight loss/BMI
Serum biomarkers
Presence of: COPD, malignancy,
diabetes mellitus

Palpable presence on exam

FVC<70%
DLCO<70%
>20% extent of disease on HRCT

Estimated sPAP >40 mmHg
Right atrial or ventricular enlargement
Septal ﬂattening
mPAP>20 mmHg
PVR  3 Wood units
Class III/IV
ECG arrhythmia, heart block, valve disease,
Diastolic dysfunction > grade 2
Left ventricular ejection fraction <45%
Severe capillary loss, with ﬁbrotic inﬁltration
Abnormal or an unusually elevated value for patient
Normotensive possible if on prednisone, vasodilators or
anti-hypertensives
Rising serum creatinine
Anti-RNA polymerase III
Frank blood on inspection
Hb < 9.6 g/dL

HAQ-DI >2.00
Weight loss > 10%
Low albumin, Low Hb
Anti-polymerase III in relation to malignancy

GAVE: gastric antral vascular ectasia, ILD: Interstitial lung disease; PAS: estimated pulmonary artery systolic pressure by Doppler
echo; HAQ-DI: Health Assessment Questionnaire-Disability Index.

thickness distribution only and provide crude sub-typing of an extremely complex disease. However,
limited sub-type may carry a higher risk of PAH, dcSSc carries higher risk for progressive ILD; and
early dcSSc with rapid increases in skin thickening is associated with new internal organ involvement [37,38], [19,39e49]. Both subtypes can develop ILD and PH, and malnutrition from severe GI
involvement.
Autoantibodies can be helpful for predicting outcome, particularly anti-centromere predicting PAH,
Scl-70 predicting ILD and RNA polymerase III predicting renal crisis (Fig. 4). Race and ethnicity are also
associated with increased risk of severe disease. Black race, compared to whites, independently predicts more rapid progression and higher mortality, more severe disease at a younger age of onset, and
with higher risk of early and concomitant ILD and PH. These racial differences may be associated with
distinct antibody and genetic proﬁles supporting that early aggressive intervention in Blacks with ILD
may offset mortality [5,32]. Hispanic and Asian ancestry also portends higher severity than whites
[50e52]. Male sex, early diffuse cutaneous disease or presence of tendon friction rubs also confer
increased risk of mortality.
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Table 2
Risk factors for the development of severe organ manifestations of systemic sclerosis [19,39e44].
Risk factors with Associated Findings
Organ manifestation
Heart

Kidney, (renal crisis)

Interstitial lung disease (ILD)

Progressive ILD

Pulmonary arterial
hypertension

Gastrointestinal

Diffuse cutaneous SSc
Elevated ultra-sensitive CRP
Myocardial ﬁbrosis on CMR
Anti-topoisomerase 1 antibody
Male gender
Pericarditis
Arrhythmia
Right bundle branch block (RBBB)
Left ventricular dysfunction
Myopathy
Tendon friction rubs
Diffuse cutaneous SSc
Rapid skin progression in the ﬁrst year of the onset
Presence of anti-RNA polymerase III autoantibodies
Medium or high dose glucocorticoid therapy, i.e. >10 mg prednisone daily
Signiﬁcant cardiac manifestation
Joint contractures
Tendon friction rubs
African ancestry
Male gender
High mRSS
Diffuse cutaneous SSc
Anti-topoisomerase I antibody (Scl-70)
Anti-Th/To antibody
Anti-U11/U12 (RNPC) antibody
Increased ESR or CRP
FVC<70%, DLCO<70%
Active polyarthritis
Increased ESR or CRP
Disease onset over 55 years
High mRSS
Reﬂux (GERD)
NYHA III-IV heart disease
Decreased SpO2 during 6 MWT
Progressive drop in %FVC corroborated by HRCT and symptoms
Advanced ILD (traction bronchiectasis, honeycombing) within 5 years of disease
onset
Disease onset over 55 years
Long disease duration
African ancestry for early onset
Skin telangiectasia (increased number and size)
Isolated DLCO decrease
FVC/DLCO ratio > 1.6
Severe Raynaud's
Severe digital ulcers
Decreased capillary density by nail fold capillaroscopy
Increased serum uric acid
Presence of anti-nucleolar (anti-Th/To, and anti-U3 RNP) autoantibodies
Disease duration
Anti-U3-RNP
Dysbiosis (microbiome composition)
End-stage vasculopathy features such as DU, calcinosis
Dysphagia
Frequent food regurgitation
Small Intestinal Bacterial Overgrowth (SIBO) and related chronic diarrhea
Chronic intestinal pseudo-obstruction
Fecal soiling
Weight loss
Low albumin/pre-albumin
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Table 2 (continued )
Risk factors with Associated Findings
Organ manifestation
Digital ulcers

Arthritis, contractures, tendon
friction rubs

Diffuse cutaneous SSc
High mRSS
Male gender
Polyarthritis
Early non-Raynaud's ﬁrst symptom
Increased capillary loss by capillary-microscopy
Early manifestation in diffuse cutaneous SSc
DAS-28
Presence of overlap SSc
Presence of anti-RNA Polymerase III and anti-Scl-70 (anti-Topoisomerase I)
autoantibodies

6MWT: 6-min walk test, CMR: Cardiac MRI, CRP: C-reactive protein, DAS-28: Disease Activity Score-28, DLCO: diffusion capacity
of the lung for carbon monoxide, ESR: erythrocyte sedimentation rate, FVC: forced vital capacity, GERD: gastroesophageal reﬂux
disorder, mRSS: modiﬁed Rodnan Skin Score, NYHA: New York Heart Association; SpO2: blood oxygen saturation; WHO: World
Health Organization.

Fig. 4. Clinical-Serologic Classiﬁcation and Internal Organ Associations (Courtesy of RT Domsic, rights reserved). ILD ¼ interstitial
lung disease; DU ¼ digital ulcers; SRC ¼ scleroderma renal crisis; PH ¼ pulmonary hypertension.

Tracking symptoms and metrics for recognition, monitoring and intervention
Any type of organized framework containing SSc domains and sub-domains that tracks changes in
clinical features, symptomatology, complications and bio-data of multiple manifestations over time,
facilitates a comprehensive and efﬁcient care continuum. This also enables communication of
important details across specialties. Such documentation captures SSc manifestations as they newly
emerge, improve, resolve, stabilize or worsen, and creates an overview that depicts treatment
responsiveness, potentially sparking consideration for new, additive or change in treatment approach.
Tables 3e6 and the resource list provide example tools.
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Table 3
Domain Organization for Clinical Assessment and Documentation in SSc. Each sub-domain is often characterized by onset,
coincident intervention, and changes over time.
Domains

Sub-Domains

Assessment Considerations

Background

Biological sex
Ethnicity and race
Environmental exposure history
Cardiovascular history
Disease Duration
Raynaud's phenomenon onset (month/
year)
What was 1st non-Raynaud's
phenomenon symptom
Onset of 1st non-Raynaud symptom
(month/year)
Physician diagnosis of SSc (month/year)
Skin Thickening
Onset month/year
Distribution (mRSS)
Pruritus
Pigmentation disturbances
Telangiectasia and Calcinosis
Vascular Manifestations Please see and incorporate components of Table
HEENT
Facial Changes
Eyes
Oral

Naso-pharyngeal

Cardiopulmonary

History of symptoms
Dyspnea/Cough/Exercise Intolerance
NYHA Symptom Category

Gastrointestinal
Consider following SCTC-GIT or
Geissen tools for overall GI
impact

Cardiac symptoms including lower
extremity edema, orthopnea
Swallowing difﬁculty

Acid related

Gastric

Biliary

Small bowel

Large bowel
Muscular

Atrophy,
Muscle strength,
Muscle endurance,
Aerobic capacity (submaximal test)
Hand grip and pinch strength
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e.g. chemicals via occupation or proximity
Especially noting hypertension

e.g. hypo-, hyer- or poikiloderma
Recorded here or under the vascular domain
7 for document template
Oral aperture
Dry Eyes
Tooth loosening, Chewing difﬁculty
Oral pain
Dry mouth
Dental caries
Post Nasal Drip (lung irritant)
Hoarseness of voice (vocal cord ﬁbrosis or acid
injury)
1st noticed symptoms to now
Tables 9 and 10 for contextualizing historytaking
Although a categorical variable that limits
utility, a worsening NYHA classiﬁcation marks
signiﬁcant clinical worsening
Arrhythmias/conduction disturbances, heart
failure
Proximal
Distal
Choking, coughing
Heartburn
Hoarseness
Cough, timing e.g. morning
History of GAVE
Early satiety
Regurgitation of food
Emesis of food
Bloating/distension/pain
History of primary biliary cholangitis
Itching, jaundice, pruritus, but may be
asymptomatic
Bilirubin and transaminase proﬁles, possible
anti-mitochondrial antibody presence
Diarrhea, pain, weight loss, malabsorption
Cramping
Bloating
Constipation
Fecal soiling
MMT-8
TST/30-sec CST^
FI-2/FI-3^
Ebbeling treadmill test*
Astrand cycle test*
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Table 3 (continued )
Domains

Joint

Sub-Domains

Assessment Considerations

AROM upper extremity,
AROM/PROM hands/ﬁngers

6 MWT*
Jamar or Grippit dynamometer*
Pinch meter*
FSA*
Goniometer*
HAMIS*
Cochin Hand Function Scale*
DAS-28

6MWT: 6 min walk test for distance, CST: Chair-Stands Test, DAS-28: Disease Activity Scale-28, FI-2: Functional Index 2, FI-3:
Functional Index 3, FSA: Function Shoulder Assessment, HAMIS: Hand Mobility in Scleroderma, mRSS: modiﬁed Rodnan Skin
Score, NYHA: New York Heart Association, *implemented routinely by OT, PT,^implemented by PT, OT but can be performed in
clinic by physician or staff.

Table 4
Snapshot diagram of common diagnostic testing in SSc.

^As indicated by history or clinical ﬁndings, SIBO: small intestine bacterial overgrowth.

Multifactorial symptomatology
This section addresses common SSc symptoms that have multiple or combined causes, approaches
to distinguishing cause(s), and where applicable, therapeutic intervention. SSc being a disease of
inciting vascular injury, special attention is given to RP in this section, though not a multifactorial
symptom, as it is pervasive and often not straightforward to diagnosis.
A. Cold in SSc, and Raynaud's Phenomenon speciﬁcally, is the most common symptom and
highest ranked SSc-speciﬁc symptom diminishing HRQoL. Without preventive and palliative

13

L.A. Saketkoo, T. Frech, C. Varjú et al.

Best Practice & Research Clinical Rheumatology 35 (2021) 101707

Table 5
Common laboratory abnormalities in SSc. Courtesy of JK Gordon & LA Saketkoo, rights reserved.
Category Speciﬁc Lab

Common Implications

Antibody Presence
ANA, bAnti-nucleolar pattern of Positive in 90e95% of cases. Perform by immunoﬂuorescence. If negative,
any titer
consider other ﬁbrosing illnesses.
a
Anti-Scl-70 (Anti70% diffuse SSc, 30% limited SSc, higher risk ILD and higher risk severe ILD
topoisomerase I)
a
Anti-RNA Polymerase III
Higher risk diffuse SSc, rapidly progressive skin, musculoskeletal involvement,
higher risk SRC, GAVE, concomitant malignancy; Raynaud may present later in
disease course
a
Anti-centromere
Limited SSc, PAH
b
Anti-Fibrillarin (U3-RNP)
Severe ILD, PAH, cardiomyopathy, severe GI involvement, diffuse SSc,
b
Anti-Th/To
Limited skin involvement, PAH, ILD
b
Anti-PM-Scl
Myositis, overlap
Anti-U11/U12 RNP
Limited skin, ILD
Anti-U1-RNP
Myositis, MCTD/Overlap, ILD, PAH, arthritis
Anti-Ku
Myositis, Overlap
Anti-NOR 90
Anecdotally associated with SSc, and other CTDs with RP; forgotten antibody
Anti-Ro52
ILD, overlap
HEMATOLOGIC
Hemoglobin/Hematocrit
GI loss, Medication effect, active inﬂammation
Schistocytes
Concern for SRC
Platelets
Elevated: Active inﬂammation,
Low: SRC, medication effect
Erythrocyte Sedimentation Rate Active inﬂammation, infection, malignancy
Serum Protein Electrophoresis Hypergammaglobulinemia
Associated with active disease, severe lung involvement, SSA antibody;
More prevalent in African ancestry
Chemistry
Creatinine
SRC related renal injury
Transaminases (ALT/SGOT, AST/ Medications, myopathy,
SGPT)
Creatine Kinase
Myopathy, myocardial infarction
Albumin
If low: Active inﬂammation, low nutrition status, malabsorption
Troponin
Myocarditis
C-Reactive Protein
Active inﬂammation, infection
Prognostic indicator
Aldolase
Myopathy
Uric Acid
Pulmonary hypertension predictor, cardiovascular disease
Pulmonary hypertension, heart failure
Pro-NT-beta natriuretic
protein/Beta-natriuretic
protein
Urine
Protein
Prognostic indicator
SRC
Red cells
SRC
a
b

Indicates criteria marker.
Indicates strong correlation with SSc diagnosis.

intervention, RP can lead to other vascular complications such as DUs, acro-osteolysis, and calcinosis
[20,53e56]. (Table 7) RP affects glabrous skin regions (ﬁngers, toes, nipples, ears, and toes). Glabrous
skin's unique vascular structure contains large numbers of cutaneous arteriovenous connections. RP in
SSc, triggered by stress or cold has variable duration and severity, generally lasts <20 min upon trigger
removal, but can endure hours or days, or establish a new baseline severity upon which exacerbations
occur.
The classic tri-phasic episodes of RP, more noticeable in lesser pigmented populations demonstrates
discoloration with distinct demarcation lines of blanching (white), cyanosis (blue/purple) and then
erythematous (red) phase with rewarming, which can be the most painful phase. Not all individuals
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Table 6
Key Physical Exam Assessments in SSc Courtesy of T Frech & LA Saketkoo, rights reserved.
Category

Assessment Area

Observed Finding

CONSTITUTIONAL

Nutrition

Pallor

Weight
Fit of clothes
Temporal muscle atrophy
Observation into room, seating,
reaching for coat, bag etc
Use of assist device for
ambulation
Observation

Lymph nodes

Palpation

General facial structural
features
a
Telangiectasia

Lip thinning

Overall mobility

HEMATOLOGICAL

HEENT
Facial appearance

Eyes
Oropharyngeal

Dryness
Conjunctival pallor
Oral Cavity

Oral aperture
Telangiectasia
Naso-pharyngeal

a

See below

Dryness
Sublingual pallor
Dentition/crowding
Aperture diameter in mm
See below
Signs of post-nasal drip (PND),
i.e., erythema, “cobble-stoning”

Comment

Anemia can occur from GAVE,
medication effect, SRC

Most facial changes are difﬁcult to
track
May indicate increasing
vasculopathy

Often the ﬁrst location to appear
PND and Reﬂux are microaspirated and irritate sensitive
lung tissue causing parenchymal
inﬂammation and possibly
worsening ILD.

VASCULAR
a

Circulation/RP

a

Digital ulcers

a

Pitting

Calcinosis

(Acro)-Osteolysis

a

Telangiectasias

- color
- coolness
- location
a
Capillaroscopy
- morphology:
Drop-out
Hemorrhage
Dilated (giant)
Tortuous
Disorganized
- number
- location
- depth
- ‘true’ vs friction
- drainage
- infection^
- number
- location
- tenderness
- number
- location
- consistency (solid v paste)
- tenderness
- infection^
Presence of distal to proximal:
- Digital shortening
- Nailbed tapering from sides
- Nailbed blunting from tip
- count
- location (inner lip, face, chest,
palms)
- matted v non-matted

Positive morphology contributes
to diagnosis.
Ophthalmoscope or
dermatoscope easily identify
morphologic changes. Nailfold
video capillaroscope can mark
detailed changes over time.

Size, draining or not

- used for diagnostic purposes
- followed over time

(continued on next page)
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Table 6 (continued )
Category

Assessment Area

Observed Finding

CARDIOPULMONARY
Cardiac

Observation

Jugular venous distension
Lower extremity edema
Positional chest pain
Rhythm, presence of gallop, rub

Auscultation

Pulmonary

Aerobic capacity
Observation

Auscultation

Oximetry

GASTROINTESTINAL

MUSCULOSKELETAL
Articular/Peri-articular

Muscle

Cough with inhalation
From apices to bases, from
beginning of inhalation to end of
exhalation
Listening for crackles, absent
breath sounds
Inspiratory cough
SpO2%/Pulse oximetry, at rest and
exertione e.g. walk to exam
room. 6 MWT

Pericarditis
Pericarditis can occur in early
phase dcSSc

Patients with ILD/PF often ‘splint’
to protect from coughing
Possible ILD/PH
If not hearing breath sounds,
instruct patient during exam.
Splinting occurs commonly in ILD
to avoid inspiratory cough.
Otherwise, consider pleural
effusion
Preferably ear or forehead
oximetry
Finger may display results not
reﬂective of true SpO2
Musculoskeletal involvement
may impact results, but overall
6 MWT can reliably tend exercise
tolerance

Aerobic capacity

6 MWT for distance

Nutrition
Abdomen

As above
Observable, palpable distension

Joint extension

To 180

Joint ﬂexion
Finger-to-palm
Tenderness ± swollen
joints
Tendon Friction Rubs

Fixed contracture (yes/no)
Palpation especially PIPs, MCPs,
wrists
Localization for documentation

Synovitis is even more difﬁcult to
appreciate in SSc than other CTDs

Observation

Mobility

Muscle involvement is:
- common in SSc
- of variable and combined
pathology: atrophy,
inﬂammatory, necrotic, ﬁbrotic
- associated with SSc cardiac
involvement

Strength/Endurance

SKIN

6 MWT
Respiratory rate
Depth of inhalation

Comment

Functional capacity
General Appearance

Atrophy
MMT 5 or 8y
Functional Index-2 (FI-2)^
FI-3-2y^

TST^or 30-sec CSTy^
Pigmentation:
- Hyper- Hypo- Poikiloderma
Sheen:
- Across chest
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PIPs, MCPs, wrists, elbows,
shoulders, knees, hips, ankle
joints

Endurance is a more revealing
assessment and more
problematic for SSc patients than
isometric strength. Usually
performed by physiotherapist.
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Table 6 (continued )
Category

Assessment Area

Breakdown

a

Thickness: Extent and
Degree
Phase of Thickness

Observed Finding
Telangiectasias (here or detailed
in ‘vascular’ domain)
Ulceration
- Digital
- Other areas
Pitting
mRSSy
- Edematous v Bound-down
- Initial signs of edematous phase
often include puffy ﬁngers; before
skin thickening occurs

Comment

Skin thickness may also impair
ROM
Edematous phase can cause
diffuse pain and itching and often
mistaken as ﬁbromyalgia.
Stretching may reduce
inﬂammation, edema,
contractures and skin tightness of
hands, ﬁngers, shoulders, chest,
hamstrings and hips; as well as
increase ROM.

a
Indicates SSc classiﬁcation criteria marker, ^Infection ¼ assessing for redness and purulence, ^see corresponding photo/s
yplease see resource list for instructional content^implemented by PT, OT but can be performed in clinic by physician or staff z

experience tri-phasic attacks, but some degree of blanching which may be difﬁcult to notice in highly
pigmented patients, supports a RP diagnosis.
While Primary RP may affect healthy individuals or be familial, SSc-RP vascular patterns are
uniquely associated with vascular injury and vasculopathy. As previously mentioned, ANA presence
with abnormal capillaroscopy predict CTD occurrence [13]. Similarly, puffy ﬁngers, SSc-speciﬁc antibodies, and abnormal capillaroscopy are highly predictive for the development of SSc [57].
The impact of RP events on vital organ vasculature or hastening PAH, is lesser known, but patients report
that episodes can result in systemic symptoms of whole-body heat loss, debilitating fatigue, headache in
addition to worsening pain of DUs and calcinosis [55,56,58]. Thus, RP worsens diffuse, diverse disability,
making recurrent preventive counselling imperative, with non-pharmacological therapy, e.g., electrical
heated gloves and treat-to-target pharmacological therapy often required [54,56,58e60].
B. Pain in SSc is often multifactorial requiring careful discernment to address coinciding diverse,
modiﬁable causes. SSc pain can be an overwhelming prospect for the clinician resulting in inaccurate
“ﬁbromyalgia” diagnoses [61]. Careful characterization of each pain type the patient is experiencing is
critical towards determining the most appropriate treatment (Table 8). For example, inﬂammatory pain
can manifest as either diffuse subcutaneous edematous tenderness, or skin-tightening, often with
accompanying pruritus, neuropathic pain from small nerve ﬁber disruption, or as joint tenderness,
stiffness or aching, or even myalgias possibly requiring systemic treatment [56,62]. While ﬁbrous
shoulder tendinopathy might require targeted physical therapy.
The presence of tendon friction rubs (TFRs), another source of pain from inﬂammation and tendon
sheath irritation, indicates active cutaneous or inﬂammatory disease that without appropriate treatment,
portends a poor prognosis including worsening skin and risk for SRC [38,62,63]. Thus, careful tendon
examination is necessary, and ultrasound can helpful to assess for active joint inﬂammation and risk for
disability [63].
Vascular complications such as ischemic RP, ischemic digital ulcers and calcinosis cause signiﬁcant,
and sometimes constant, pain even at rest [55]. Increased intensity of pain and local tenderness may
also signal concomitant infection; however, calcinotic lesions are frequently painful in the absence of
infection depending on location. Large lesions can occasionally lead to nerve impingement resulting in
neuropathic pain symptoms.
Pain and discomfort related to the GI system in SSc is diverse. Dry mouth, oral thrush, odynophagia
from esophageal candidiasis, abdominal pain, and cramping from obstipation or distention are
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Initial History

Current & Past Symptoms

Physical
Function/Self
Esteem

Exam

Counselling Considerations

Therapeutic Considerations

Raynaud (RP)

- 1st RP recollection
- Provoking factors
- Location
- Frequency
- Pain
- Duration of attack
- Medication use
- History of:
Gangrene,
Surgical amputation,
Sympathectomy,
Botox injections
- Location*
- Number
- Concurrent infection
or gangrene
- Duration

- Pain sensation quality and
intensity (numbness,
tingling, burning stinging,
pain)
- Location (ears, nose,
ﬁngers, nipples, toes)
- Frequency
- Color changes

- Impact on
social life
- Impact on
employment

- Acro-osteolysis

- Stress management
- Warming measures
- Discontinue exacerbating
medications
- Avoid tobacco

- See table below for medications

Severity of Pain
- Infection
- Size
- Location
- Frequency
- Duration

Impact on
social life
- Impact on
employment

-

- Identifying
critical digital ischemia

- RP prevention
- OT
- Wound care
- Salves
- IV prostacyclin
- See table below for medications
*Ulcers can appear in other locations

-

- Impact on
social life
- Impact on
employment
– Impact on
social life
- Impact on
employment
- Impact on
joint function
or contractures
- Impact on
social life
- Impact on
employment
Impact on selfesteem,
intimate life

- Number
- Size

Protective measures

- Number
- Size
- Location
- Attachment to
tendons, ligaments,
muscle planes

- Measures to protect site
from trauma
- Surgical options

-

- Number
- New lesions from last
exam
- Location

Cosmetic
options

- Laser beam therapies

Aerobic exercise may help,
attention to cold
prevention may help e.g.
core warmth

Referral to ED specialist, aerobic exercise

Digital Ulcers
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Pitting

- Location
- Pain

Calcinosis

- Location
- Pain
- Drainage

Telangiectasia - Location
- Change in number

Erectile
Dysfunction
(ED)
GAVE
PH

- See below
- See below

Pain
Numbness
Location
Frequency
Pain
Drainage
Location
Surgical needs

- Location
- Treatment

Number
Location
Size
Infection
Gangrene

RP treatment
RP prevention
Trauma prevention
Surgical removal
Possible IV prostacyclin
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Table 7
Vascular history, physical, counselling, therapeutic considerations. (Table courtesy of T Frech and LA Saketkoo, rights reserved).
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common pain sources that patients experience. Opioid analgesics require careful consideration for
worsening SSc-symptoms, e.g., sicca, GI motility, with initiation of preventive regimens being
important.
C. Fatigue in SSc, another potentially overwhelming clinical consideration, impacts all areas of daily
living, work, parenting, and social participation. There are many types of fatigue: mental/cognitive,
motivational, physical, muscular, general, etc. Although a nonspeciﬁc symptom, fatigue can be evidence of several serious SSc complications such as GI bleeding, ILD, or PH. Fatigue may also reﬂect
worsening inﬂammatory disease, malnutrition, poor sleep quality, gastroesophageal reﬂux (GERD), or
the burden of decreased physical function. Further, dyspnea and cough episodes with longer recovery
times are exhausting symptoms with high calorie demand and psychological burden. An organized
approach to assessing and addressing fatigue can guide investigation.
Sleep disordered breathing risk is signiﬁcantly elevated in SSc and beyond inducing fatigue likely
impacts cardiopulmonary health [64,65]. Epworth Sleepiness Scale and the STOP-BANG questionnaire
help identify those patients at risk for OSA and qualify for a sleep study. If warranted, CPAP use improves fatigue and potentially prevents SSc cardiopulmonary and esophageal complications [66].
However, as with breathlessness, fatigue in SSc can result from commonplace co-morbidities requiring
investigation, such as hypothyroidism and coronary artery disease.
D. Breathlessness and Exercise Intolerance in SSc is often multifactorial and can be related to
myriad, sometimes severe, complications beyond cardiopulmonary involvement, and like fatigue requires thorough investigation. Breathlessness is the most common symptom of ILD, PH, and myocardial
disease. However, its development is often quite subtle, and patients may not recognize or explicitly
complain of dyspnea. Careful questioning of patients' activity and changes in activity over time is
necessary to determine if there has been a signiﬁcant change (Table 9). Careful historical probing may
reveal a history of decreased exercise tolerance, changes in the intensity and duration of daily activities
and an unconscious slowing of movement. Further these changes may be apparent to patients’ loved
ones when not overtly apparent to the patient themselves. Therefore, screening requires physicians
asking appropriate questions and patients recognizing changes to determine if dyspnea is present.
Dyspnea or coughing with deep inspiration or activities that engage deeper inspiration such as
laughing, sneezing walking-talking suggest a restrictive process like ILD [67e70]. ILD, PH, anemia,
heart involvement, physical deconditioning, and anxiety are common causes of dyspnea in SSc and are
not mutually exclusive (Table 10).
E. Cough in SSc, the second most common symptom of ILD, is associated with increased ILD severity
and worse HRQoL [7,8]. Cough, though, is often multi-factorial and requires careful historical assessment to differentiate the causes, e.g., ILD, reﬂux, post-nasal drip (PND), or sinus problems. A dry,
inspiratory cough limiting inspiratory depth is often ILD-related and can trigger frightening, embarrassing, exhausting and inconvenient episodes dyspneic coughing that usually have prolonged recovery phases [67e70]. Patients often restrict inspiration to prevent this from happening [67e70]. The
quality of cough varies in patients with SSc-ILD with >50% of patients reporting a cough productive of
sputum [8,71].
Dysphagia and GERD with micro- or macro-aspiration may produce a wet, post-prandial, or early
morning cough that often clears or lessens during the day, but recurs at night. However, a dry cough
related to GERD can also occur from pulmonary irritation. SSc-ILD patients with GERD reported cough
signiﬁcantly more frequently than SSc-ILD patients without GERD [8]. PND can also cause a wet or
throat-irritating cough. Cylindrical bronchiectasis, weakening of bronchiole walls creating mucous
stasis and sub-acute infection (as opposed to traction bronchiectasis, an extrinsic force causing bronchial distortion often seen on HRCT in ILD) is not uncommon in CTDs often occurring with productive
cough that comes and goes, and often improves with antibiotic therapy.
System-based symptomatology and management
A. Gastrointestinal System manifestations occur in virtually all SSc patients from the oral cavity
through the lower GI tract and anus (Fig. 5). Gastrointestinal symptoms are associated with higher
patient-perceived disease severity and lower HRQoL when compared with traditional SSc severity
measures (PH, ILD, renal and cardiac) [54,56]. Multiple and diffuse morphological and functional GI
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Table 8
Modiﬁable causes and treatment of fatigue and pain in SSc. (Table courtesy of LA Saketkoo, rights reserved.)
Symptom

System/Origin

Potential Causes

Fatigue

Anemia

GI loss, chronic inﬂammatory
disease
PH, diastolic HF, CAD, physical
deconditioning

Cardiac

Respiratory
Muscular

Systemic inﬂammation

Psychological

Neurological
Malnutrition
Sleep-related

Medication-Related
Pain/Dysesthesia

Vascular

PH, ILD, OSA
Low muscle endurance, muscle
strength or reduced aerobic
capacity
Effects on hypothalamic axis,
causing systemic malaise,
effects on muscle
Anxiety, depression, fear,
impact of reduced self-esteem
and self-image
Pain: ischemic, edematous skin,
articular, restless leg syndrome
Weight loss, malabsorption
OSA, nocturnal pain, pruritus,
GI symptoms, depression,
anxiety, steroid or opioid use
Methotrexate, MMF, nintedanib
etc.
Raynaud

Digital ulcers

Calcinosis
Infected digital ulcers/calcinosis
Dermal

Skin tightening
Subcutaneous edema and
pressure
Pruritus

Musculoskeletal

Myopathy/Myalgias

Fibrous tendinopathy
Inﬂammatory arthropathy/
tendinopathy

Gastrointestinal

Genitourinary

Secondary ﬁbromyalgia
Heartburn
Abdominal cramping
Abdominal bloating
Dyspareunia
Vaginal dryness
Erectile dysfunction
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Team Involvement/Interventions

PT and PR teach adapted aerobic and
muscular exercises, and breath pattern
training
OT teaches energy conservation
strategies such as pacing, prioritizing
and accommodating devices
OT, PT, PR as for cardiac
MT, MMM, PR-PTr, PT for Aerobic
exercises, muscle strengthening and
endurance exercises, education
Immunosuppression, exercise

MT, MMM, PR-PTr, PT, OT, Breath
pattern training, Psychologist, Social
Worker
Assess treatable causes, MT MMM, PR
Dietary and nutritional counselling
SH, RSS, MMM, MT

EC preventive strategies, MT,
vasodilators, PT for aerobic exercise to
improve blood ﬂow
Sympathectomy for critical ischemia
EC wound care, protective dressing,
anesthetics, OT for daily activities, MT,
PT as for RP
As above, UTPRM: soaking for relief
EC red ﬂags, Aerobic exercise to
improve circulation
PT, ST, OT for stretching and
manipulation
MT,ST, OT as above
MT, SH, ST, opioid receptor blocker,
phototherapy
MMM, OT, PT, PR-PTr, for strength,
endurance and anti-inﬂammatory
effects of exercise
MMM, OT, PT, THE as above
MMM, OT, PT, ST, local injections,
muscle strengthening, stretching,
targeted hand exercises
MMM, PR-PTr, SH, education
EC, RH, NH, anti-acid and PPI
See below
Pelvic ﬂoor therapies, sometimes
systemic treatment
Lubricants, topical estrogen
Vasodilators, PT for aerobic exercise,
specialist referral
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Abbreviations: AG ¼ anticipatory guidance, ATT ¼ assessment with targeted treatment, EC ¼ education /counselling,
DHS ¼ dental hygiene strategies, ILD ¼ interstitial lung disease, MMM ¼ mindful movement modalities (e.g. gentle yoga, tai chi
etc), MT ¼ mindfulness training strategies, OSA ¼ obstructive sleep apnea, OT ¼ occupational therapy, NH ¼ nutrition hygiene
(EC on attention to selection, volume, texture, preparation, combination strategies of foods), PAH ¼ pulmonary arterial hypertension, PPI ¼ proton pump inhibitors, POS ¼ practical organizational strategies, PT ¼ physiotherapy, RH ¼ reﬂux hygiene
(including head of bed elevation), RHS ¼ refer to hand specialist, RME ¼ refer to motility expert, THE ¼ targeted home exercises,
PR ¼ pulmonary rehabilitationist, PR-EC ¼ pulmonary rehabilitation educational component, PR-PTr ¼ PR physical training
component, RSS ¼ refer to sleep specialist, SH ¼ sleep hygiene, SR ¼ specialist referral, ST ¼ systemic treatment,
UTPRM ¼ untested patient-reported management[10]

Table 9
Screening questions to help patients reﬂect on potential onset and changes in dyspnea and cough. Courtesy of LA Saketkoo,
rights reserved.
Dyspnea screening

Cough screening for ILD

Do you notice being more short-winded now than one
month ago, six months ago, last year while doing activates
(consider likely activities for the patient)?
Do you notice it takes you longer to vacuum, mop, make the
bed, mowing the lawn?
Do you notice that you need to take more breaks when
vacuuming, mopping, etc.
Do you notice you are becoming more short of breath when
vacuuming, making the bed, mowing the lawn?
Are you able to keep up with family members/peers when
walking?
Do you feel they slow their pace for you?
Do you ﬁnd it difﬁcult to walk and talk at the same time?
Do you feel that bending over takes your breath away?

Have you been coughing? More in the past 3/6 months?

Do you cough when taking a deep breath in?

Do you cough with laughing or sneezing?
Do you cough while talking?

Does coughing make you feel short-winded?

Table 10
Common causes of dyspnea and cough in SSc. Courtesy of LA Saketkoo & MB Scholand, rights reserved.
Dyspnea

Cough

ILD
Pulmonary Hypertension e any or any combination of the
following: Groups I, II, III, IV
Bronchiectasisa
Cardiac dysfunction or arrhythmia
Anemia
Physical deconditioning
Intrinsic or extrinsic myopathy e.g. restrictive truncal skin
involvement (carapace chest), accessory muscle
myopathy
General population considerations: CAD, COPD
Disordered breath patterns

ILD e dry inspiratory
PND e possible drip sensation, often in morning, sore throat
Bronchiectasisa
Heart failure
GERD e can be ‘wet’ cough/gastroparesis

a
Bronchiectasis can be either traction (extrinsic pulling and distortion of the bronchioles often seen in pulmonary ﬁbrosis on
HRCT) or cylindrical (laxity of the bronchiole wall either due to infection or perhaps CTD itself, creating a stasis environment for
bacteria; cough is often productive).

abnormalities result in high degrees of symptom distress, life disruption and diminished HRQoL. These
destructive changes are hypothesized to result from progressive sub-/mucosal inﬂammatory-ﬁbrotic
inﬁltration and vascular insufﬁciency, leading to neuronal dysfunction, and subsequently to dys-/
non-motility.
Oro-maxillary and pharyngeal structural changes with painful or difﬁcult mastication and swallowing; esophageal dysmotility with dysphagia; malnutrition from malabsorption or decreased intake;
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Fig. 5. Depiction of the diffuse nature of gastrointestinal involvement in SSc. Courtesy of T Frech, rights reserved.

L.A. Saketkoo, T. Frech, C. Varjú et al.

Best Practice & Research Clinical Rheumatology 35 (2021) 101707

gastroparesis with bloating, nausea/emesis; colonic inertia with constipation; bacterial overgrowth
with bloating, abdominal distension and diarrhea; and loss of anal sphincter tone resulting in fecal
incontinence. Dysmorphic surface vessels, vulnerable to abrasion, such as arteriovenous malformations and gastric antral vascular ectasia (GAVE), may cause symptomatic anemia with dyspnea/fatigue
due to slow or rapid blood loss.
Patients express frustration that despite extent and severity of GI manifestations in SSc, rheumatologists generally avoid GI-related discussion. Anecdotal clinical evidence and patient discussions
support that systemic treatment in early SSc disease e as with ILD - may prevent or reverse GI
symptom progression.
While esophageal involvement is the most common aspect of GI involvement, weight loss, diarrhea,
and fecal soilage can indicate the presence of small bacterial overgrowth requiring treatment [72].
Additionally, micronutrient deﬁciency and malnutrition is a concern in SSc and patients’ appetite and
dietary intake should be assessed [43]. Working closely with a dietician and gastroenterologist to help
guide diagnostic and therapeutic interventions can help with the management of SSc GI involvement
[73].
Gastroesophageal Reﬂux Disorder (GERD), a manifestation with far-reaching detrimental effects on
the esophagus and the lung, demands dedicated robust attention. The ongoing injury caused to the
esophageal mucosa puts patients with SSc at higher risk of pre-malignant and malignant injury, as well
as structural abnormalities such as webbing, scarring, and the development of strictures. The injury to
associated neuromuscular complexes results in dysphagia and poor acid clearance. The absence of
heartburn or regurgitation are often discordant with endoscopic ﬁndings of esophageal injury and pH
testing. Prior to proton pump inhibitor (PPI) introduction, inability to eat from severe esophageal
dysfunction, was a major cause of malnutrition and mortality. The advent of PPI use, effected a signiﬁcant decrease in esophageal strictures. Further, the extent of ILD and lung parenchymal inﬂammation is associated with degree of GERD and uncontrolled GERD, and hypothetically PND poses a
similar concern. Chronic GERD or PND can cause hoarse voice or dysphonia. Guideline-based care
highlights the value of a multidisciplinary approach and the role for diagnostic testing [74].
Severe GERD may not be symptomatic, as early stages require signiﬁcant neuronal recruitment and
in later stages nerves may be dysfunctional to pain perception e but ongoing injury will still occur. The
SSc specialist community is largely of the opinion that beneﬁt of empiric PPI use in SSc-GERD outweighs the risks. Often, standard dosing of PPIs may require increased frequency and possibly addition
of other agents such as histamine-2-blockers (H2-blockers), e.g., famotidine, or coating agents such as
sucralfate. Use of these therapies may require attention to timing of administration to avoid drug-drug
interactions [75].
However, it is essential that anti-reﬂux measures are thoroughly explained and strictly practiced.
This includes: elevation of the head of the bed to 60 degrees by wedge pillow, mattress elevation,
bricked bed legs or automatic adjustable bed; and avoidance of right-side sleeping as gastric contents
will spill back toward esophagus. For patients using CPAPs, we underscore that adherence can help to
suppress reﬂux [66].
B. Cardiopulmonary involvement
Pulmonary involvement in SSc
ILD and PH are the leading causes of SSc-related death. Identifying these entities early and initiating
early appropriate treatment prolongs survival [2,9,10]. Initial screening in all SSc patients with pulmonary function testing (PFTs) including diffusion capacity of lung for carbon monoxide (DLCO) and
high resolution CT scan (HRCT), as well as exercise tolerance are key to detecting important changes
that reﬂect developing cardiopulmonary involvement (Diagram 1).
It is essential in SSc care to recognize that 1. ILD behavior is variable across patients (e.g. stable,
slowly progressive, rapidly progressive), can change over time and requires an individualized and
vigilant approach, 2. ILD and PH often coexist, combined PH/ILD occurs much earlier in patients of
African descent, 3. Patients with SSc are vulnerable to developing: a) either PH WHO Group 1, 2, 3, or 4,
each requiring different therapeutic approaches b). Coexistent PH group types (e.g. combined WHO
Groups 1 PAH and 2 diastolic dysfunction, combined WHO Groups 1 PAH and 3 ILD), 4. Screening,
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Diagram 1. Proposed Screening and Monitoring Algorithm for Clinically Signiﬁcant SSc-ILD. Courtesy of LA Saketkoo, rights reserved.

detection, characterization of PH Group type, and initiation of appropriate treatment demand adherence to clinical diagnostic algorithms and tracking of patient symptoms (Table 11).
Though, without formal consensus amongst SSc specialists, HRCT is the gold standard to screen for ILD
in SSc. Numerous studies demonstrate that PFTs are inadequate in detecting ILD in this population,
particularly in the early stages [71]. However, insurance constraints may limit the ability to obtain HRCT
in a limited cutaneous, asymptomatic patient with normal PFTs. Follow-up PFTs with careful trending are
crucial. Repeat HRCT is indicated for unexplained symptom changes (dyspnea, cough), PFT worsening
(drop 10% in FVC or 5e10% fall in FVC with 15% decrease in DLCO) to investigate co-existent infection
or malignancy versus progressive ILD. Bronchoscopy is reserved for co-existent concern of infection or
malignancy. Lung biopsy is not warranted for diagnosing SSc-ILD in patients with SSc with a typical HRCT
pattern i.e. usual or non-speciﬁc interstitial pneumonitis (UIP or NSIP).
Documenting serial PFT data along with temporally coincident medication dosing and any
contextual factors that might explain an aberrant PFT performance on that day (e.g., sinusitis or allergies) is an essential investment in the care of SSc patients. Charting the trajectory beginning from the
ﬁrst available PFTs affords insights into disease behavior, e.g., rapidly progressive vs. stable vs. slowly
progressing ILD [76]. Furthermore, it can prevent the clinician from overlooking progressing disease in
the context of normal range values, as a 5% decrease in FVC over 6 months (or 10% annually) despite
normal values warrants investigation and possible modiﬁcations or additions to treatment.
Though serial FVC is considered a reliable reﬂection of restrictive lung disease, DLCO can be a key
differentiator between parenchymal versus vascular lung disease, and provide an early detection
mechanism for pulmonary hypertension. While FVC reﬂects restriction related to parenchymal lung
disease, DLCO reﬂects the ability of gas to cross from airspace to bloodstream which requires gas to
diffuse across two barriers: the lung parenchyma and also the blood vessel wall (Fig. 6). If either or both
are resistant to permeable gas, as can occur in SSc-ILD or SSc-PH this will cause reduction in DLCO. In
parenchymal disease the FVC and DLCO commonly trend downward in parallel; while in vascular disease
the DLCO has a much steeper decline than FVC (Fig. 7). However, early in the course of SSc-ILD, the FVC
may be normal, while the DLCO is often decreased. Over the course of SSc, the FVC:DLCO ratio may help
distinguish pulmonary vascular disease from progression of SSc-ILD with a higher ratio suggesting a
predominant pulmonary vascular process [77,78]. Therefore, in addition to yearly screening echocardiogram (ideally at rest and with exercise), DLCO is an important indicator of pulmonary vascular
involvement.
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Table 11
Screening and characterization of pulmonary hypertension in SSc. Courtesy of LA Saketkoo, rights reserved.

Cardiac Involvement in SSc
Cardiac Involvement in SSc may result from microvascular insufﬁciency, or inﬂammatory-ﬁbrotic
inﬁltration of the myocardium, causing arrhythmias, diastolic or systolic dysfunction, pericarditis, or
myocarditis which are managed similarly to non-SSc cardiac complications. Cardiac involvement was
often found to be associated with SSc-myopathy in several studies [79e83]. SSc-speciﬁc treatment is
yet unclear and likely depends on suspected disease activity. Baseline/annual echocardiogram serves as
a comparison should cardiac problems or PH develop later. Non-contrast cardiovascular magnetic
resonance (CMR) demonstrates 45% prevalence of myocardial ﬁbrosis unexplained by other causes and
often associated with diffuse skin involvement and elevated ultra-sensitive CRP; CMR may play a role
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Fig. 6. Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) Measures the Ability of Gas to Transfer Across Two Pulmonary Barriers: Parenchyma and Vascular (illustrations courtesy of LA
Saketkoo, rights reserved.).
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Fig. 7. DLCO behavior in ILD versus PH Predominance. The closer the ratio of FVC:DLCO is to 1 the more likely abnormal DLCO
changes are related to restrictive lung disease. (illustration courtesy of LA Saketkoo).

in early diagnosis [79,84e86]. Additional serum biomarkers that are commonly followed as predictors
of onset and worsening are NT-Pro-BNP and uric acid, of which NT-Pro-BNP has demonstrated reliable
properties.
Routine cardiovascular risk reduction with blood pressure monitoring and lipid screening is
encouraged in SSc patients.
When to consider transplantation
Despite prior misconceptions of worse outcomes for patients with SSc (for ILD, PH, or both)
compared to those with non-SSc lung disease, lung transplantation in SSc is safe, with similar survival
outcomes. Lung transplantation is reserved for patients whose lung disease progresses despite
maximal systemic therapy. (Table 12). Early referral for transplant evaluation permits time for patients
and caregivers to become familiar with the transplant process, make informed unhurried decisions,
and adjust to psychosocial and ﬁnancial pressures related to transplant.
Most common barriers to lung transplant in patients with SSc can be overcome (Table 13). Physical
conditioning is an important factor in transplant selection and successful post-transplant recovery.
Early referral gives patients who are deconditioned an opportunity to engage in healthy lifestyle
changes and home ﬁtness practices supported by pulmonary rehabilitation.
Table 12
When to consider referral for lung transplant.
Diagnosis

Indications for Referral

Interstitial lung disease

 Radiographic or biopsy proven disease
 FVC  80%
 Need for supplemental oxygen
 Severe functional limitation with NYHA functional class III or IV
 Rapid decline in functional status
 Decreasing 6 MWT
 Increasing oxygen requirements
 Need for intravenous therapies
 RV failure without evidence of RV infarction (isolated RV failure related to pulmonary
hypertension [any WHO class] recovers after lung transplant)
 Irreversible LV involvement, heart-lung transplant evaluation may be warranted

Pulmonary hypertension

Myocardial disease

Abbreviations: 6MWT, 6-min walk test; FVC, forced expiratory volume; LV, left ventricle; NYHA, New York Heart Association;
RV, right ventricular; WHO, World Health Organization
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Table 13
Common challenges of lung transplant evaluation in patients with systemic sclerosis.
Challenge

Considerations

Obesity

 BMI <35, preferably <30 and transplant center dependent
 Early counselling regarding healthy weight
 Highly variable and transplant center dependent
 Pulmonary rehab participation
 Frailty Assessment Score
 Chronic pain/Advanced osteoporosis
 6 months sobriety with only rare exceptions
 Participation in counselling
 Full evaluation of esophagus
 GJ tube for full nutritional support may be recommended, assessment for
willingness and compliance
 Time free from malignancy is multifactorial and transplant center dependent
 Identify 24-hour caregiver for at least 3 months
 Some transplant centers also require a committed back-up caregiver
 Caregivers will be evaluated for appropriateness
 Financial counselling to establish ability to afford transplant
 Fundraising may be required/recommended
 Insurance clearance required before evaluation is initiated

Age
Frailty/Deconditioning/Post-transplant
rehabilitation potential
Active substance abuse/dependence
Esophageal dysmotility

History of malignancy
Social support

Finances

Abbreviations: BMI, body mass index; GJ, gastrostomy-jejunostomy

Table 14
Common Therapeutic and Surgical Referrals Resourced in SSc Care. Cultivating referral relationships with colleagues who
are interested in SSc may have best outcomes for people living with SSc.
Therapeutic/Surgical

Indications

Occupational Therapy

For hand, face and oral health
Joint and skin mobility
Self-management, breath pattern training
Home and work adaptations
Early referral (to establish therapeutic relationship under non-urgent
conditions) for patients at high risk for vascular or wound complications
including:
Critical ischemia
DUs/calcinosis complicated by infection
Calcinosis complicated by nerve entrapment
Macrovascular occlusion
For procedures including sympathectomy, botulin toxin injections
For building muscle strength, muscle endurance and aerobic capacity
Increasing physical capacity and activity
Balance, joint/skin mobility
Education on fatigue and pain
For enhancing aerobic capacity, endurance and education on cardiopulmonary
efﬁciency
Includes Singing, Yoga, Dance for Lung Health programs
At least twice yearly
Access to pediatric dendistry is a consideration
Dry mouth care
Preservation of dentition
For swallowing, mouth strengthening exercises and speech production
To enhance calorie intake, detailed counselling on gastroparesis and food
tolerance strategies
Management of DUs, calcinosis
For DUs, avascular necrosis, general wound healing
For managing anxiety, depression, impact of changing appearance on body
image and self-esteem
Developing coping skills to manage changing ability, uncertainty

Hand Surgery
Vascular Surgery

Physiotherapy

Pulmonary Rehabilitation

Dental care/Oral surgery

Speech
Nutrition/Dietetic Care
Wound Care
Hyperbaric Therapy
Psychological Support and Counselling
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Fig. 8. The Renal Crisis Prevention Card may help patients direct emergency healthcare providers to abort a crisis and avoid adverse
outcomes [83].

Potential transplant candidates with SSc undergo extensive testing to identify needed interventions for
SSc manifestations that might overtime injure the allograft, e.g., partial/modiﬁed Nissen fundoplication for
severe GERD or heart-lung transplantation with coexistent irreversible myocardial disease. Severe
esophageal dysmotility or GERD (lower esophageal sphincter incompetency) lead to chronic aspiration
which poses signiﬁcant risk for acute and chronic allograft rejection, may also warrant GI tube for nutrition
post-transplantation.
C. Muscle Involvement in SSc is under-recognized, prevalent and multifactorial. It ranges from
atrophy, inﬂammatory, vasculopathic, ﬁbrotic to necrotic pathology. Both muscle strength and
endurance in proximal muscles are commonly reduced, especially in patients with signiﬁcant lung
disease [86]. Systemic treatment and exercise can improve SSc myopathy, with physical therapy that
targets strengthening and prevention of large joint contracture, particularly in the shoulders (Table 14).
Consideration of medication-related myopathy culprits, such as statins, steroids, and hydroxychloroquine, is a mainstay of assessment. SSc-myopathy predicts SS-related cardiac involvement
[79,82e85].
D. Hands in SSc are especially subject to diffuse morphological changes, impairment, and pain due
to inﬂammation, vasculopathy and ﬁbrosis. These pathological processes result in bony, periarticular
and cutaneous destruction with infection, ulceration, calcinosis, acro-osteolysis, ﬂexion contractures,
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Table 15
Essential counselling on exercise in SSc. Note: in many countries, physiotherapists also teach breathing exercises to optimize
breath patterns and strength of breath. General exercise applications are also a part of cardiopulmonary rehabilitation programs.
EXERCISE GENERAL STRETCHING
APPLICATION

RESISTANCE

AEROBIC

MONITOR

Ideally >15 reps for 3
sets at least twice a
week
To gain muscle mass
To preserve overall
muscle strength

Warm-up and cooldown important
esp PAH, treadmill,
ergometer cycle
Ideally 30 min, 3
days/week

At least initially with PAH
and/or ILD: SpO2, heart
rate, blood pressure.
Dyspnea and muscle
tiredness with Borg CR-10
and exertion with Borg RPE

GENERAL
Both upper and lower
extremities with
dedicated focus on
areas with impaired
range of motion (e.g.
shoulders/pectorals,
calves, hamstrings and
external rotators in
hip).
Easier to do when
warm, after exercise or
sauna
OROFACIAL
Isometric-hold positons N/A
Emphasize
- see resources
-mouth opening
-facial grimaces such as
smile, pucker lips, etc

-use ruler to monitor
- see resources section

HANDS
Emphasize
-Flexion MCP and IP
joints
-Extension PIP joints
-First commissure
-Finger web spaces
(interdigit)
-Wrist ﬂexion and
extension

N/A
-Squeezing foam,
dough, putty
-Finger extension with
rubber bands/putty for
resistance
-Rolling out dough/
putty with ﬁnger
-Pinch with foam,
dough, putty (ﬁnger
tips to thumb, thumb to
side of index ﬁnger)

Hand tracings:
- In extension
- In ﬁst
Grip and pinch strength
- see resources section

Heat modalities prior to
stretching enhances
practice (e.g. parafﬁn
wax, warm water, etc)
Abbreviations: N/A ¼ not applicable, MCP ¼ metacarpophalangeal joint, PIP ¼ proximal interphalangeal joint.

synovitis, tendinopathy and amputation. Arthritis, contractures, tendon friction rubs come early during
the disease course, therefore require early intervention. The role of hand exercises in SSc is critically
important. Exercise improves circulation, healthy vascular and skin repair, increases warmth, reduces
local inﬂammation and stiffness, and very importantly, increases muscle strength and hand function.
Preventive strategies to maintain hand warmth may help to prevent further vascular injury (Table 14).
E. Renal Involvement in SSc: prior to the availability of Angiotensin Converting Enzyme (ACE)
inhibitors renal crisis was the leading cause of death in SSc. Early intervention with ACE inhibitor
therapy and rapid control of blood pressure may abort a “crisis” and minimize renal damage. However,
with close monitoring of high risk patients including prednisone use >10 mg/day, abrupt and severe BP
elevation, presence of anti-RNA polymerase III, we can identify and aggressively treat SRC. Late
recognition, delayed or inappropriate therapy persist and result in renal failure and other complications of malignant hypertension. Despite progression to end-stage disease, with continued treatment
with ACE modulation, renal function may return months even after initiating dialysis. Educating patients at higher SRC risk on warning signs and plan of action is crucial to improving outcomes, including
consideration of home blood pressure monitoring, and providing the “renal crisis prevention card”
(Fig. 8) on a patient's ﬁrst visit for use in emergent situations [87].
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Table 16
Key Elements of Recurrent Counselling (Courtesy of LA Saketkoo, rights reserved).
Category

Sub-Category

Item

Advisements for Patients

Raynaud

Prevention is key

- Related complications include DUs, calcinosis,
osteolysis and core temperature loss
- Initiate protective measure in anticipation of and upon
noticing a cold atmosphere, before allowing oneself to
‘feel’ cold
- Immediate action can result in decreased recovery
time, pain and the sequela associated with loss of core
warmth (fatigue, headache, incapacity etc.)
- Avoid extreme temperature changes, e.g. from cold to
warmth
- Anticipate cold environments, e.g. air conditioning in
summer, grocery store freezer aisle, hospitals etc.
- Exercise/movement increases circulation and body
heat
- Clothes layering and use of insulated vests
- Gloves/socks always at hand
- Should allow for a thin space to trap a warming layer
of air
- Pocket hand warmers, can be placed in pockets, gloves,
socks, undergarments
- Heated gloves/insoles/shoes
Cushioned bandages for high friction areas
Waterproof gloves for washing or handling wet items
Bandage and gloves for handling dry household items
potentially snagging healing ulcers and to protect from
bacteria and chemical irritants
Exercise gloves for use of gym equipment
- Protection as above - Topical lidocaine
- Cleansing routine
- Increased pain/tenderness
- Redness
- Purulence
As much as possible avoid:
- Cold exposure
- Trauma
Topical antibiotics with signs of infection
- Avoid digging to prevent infection
- If intolerable can try repeated soaking in warm Epsom
salt water
- Topical antibiotics
- Increased physical activity may help protect
circulatory and neuronal function
- Preventive measures as for RP might have a protective
effect

VASCULAR

Core Temperature

Peripheral

Digital Ulcers/Calcinosis Protection

Pain management
Signs of infection

Prevention

Additional calcinosis

Advisement

Erectile dysfunction

NUTRITION
Calorie intake

Nutritious

Food Tolerance

Nutritious

- Avocado
- Nuts, nut butters
- Cheeses, butter
- Potatoes, rice
- Olive and other oils
- Pureed foods (soups, dips, stews)
- Smaller amounts of a food
- Foods softened (marinated) with small amounts of
citrus or vinegar
- Mobility after eating to increase motility

HEENT
Oro-facial

Facial Exercises and Massage for skin tightness, mobility
and circulation

Oral
(continued on next page)
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Table 16 (continued )
Category

Sub-Category

Item

Advisements for Patients
High risk for dental complications:
- Essential follow-up with a dental clinician sensitive to
SSc care or perhaps pediatric dentist
- Proactive dental care
- Keeping mouth moist
- Adapted and powered devices for teeth and oral care
Wetting and pro-salivation products
Possibly singing, humming, chanting and exercise

SICCA
CARDIOPULMONARY

PH and Cardiac

GASTROINTESTINAL
GERD

Monitor for symptoms
of heart failure

Esophageal Injury &
Lung Risks

Graded exercise essential to health
Control of GERD and PND to avoid lung injury from
micro-aspiration
Vaccination for prevention of infection
Daily weights as needed; recording of post-void
morning weight
Alert MD of new onset lower extremity edema

Reﬂux in SSc is a serious issue of which related injury
can lead to multiple complications that impact
mortality.
- Often exists without pain
- Pain not equate severity
- Esophagitis
- Esophageal cancer
- Dysphagia and potential loss of swallow function
- Strictures & Webbing
- Need for esophageal stretching
- Acid aggravates lung disease
Medications
- PPI daily or twice daily, especially with esophagitis or
esophageal ulcer
- Adding PRN or OTC agents (e.g. sucralfate, H2
blockade)
– it is perceived that in SSc the beneﬁts of PPIs greatly
outweigh associated risks
Sleep Essentials
- Head of Bed Elevation (wedge pillow, leveraging
mattress, bricks/books under bed legs)
- Avoid right side lying
Reﬂux hygiene
- Smaller, more frequent meals
- Avoid meals 2e3 h before lying
- Avoid sphincter relaxants at end of day e.g. alcohol,
chocolate, caffeine, mint etc.
Gastroparesis
- Sleep and hygiene as for GERD
- Exercise/walking may help
- Gravity strategies for passive digestion
- Upright position
- Attention to food consistency e.g. thinner foods
- Gastroparesis dietary suggestions for food tolerance
Bloating
- Exercise for motility
- Small frequent meals
Nausea
SSc or Medication related - Mobility/exercise to decrease nausea
- Ginger sweets, drink
- Sucking candies
- Cold pops
- Instruction on PRN anti-emetics
Diarrhea
SSc or Medication related Logistics until controlled: change of clothes, time
planning
Medication use: risks/beneﬁts/when
MEDICATION See Appendix of Medications
VACCINES
See Table 17
Pneumococcal immunizations per CDC guidelines
Inﬂuenza annually
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Table 16 (continued )
Category

Sub-Category

Item

Advisements for Patients
Herpes zoster (killed only i.e. Shingrix)
COVID-19

EXERCISE
Improves:
- Circulation and vascular responsiveness
- Body warmth
- Sleep
- Self-Esteem
- Breathlessness
- Joint mobility stiffness and lubrication
- Skin function
- GI function
- Possibly erectile function
- Nausea
- Salivation
- Respiratory performance
- Cognitive clarity
Decreases:
- inﬂammation
- Pain (anywhere)
- Joint stiffness
- Possibly contractures
- Possibly skin tightness
- Depression
- Stress
- Fatigue
WOMEN OF CHILD-BEARING AGE
Medication toxicity

- Use of contraception essential with speciﬁc IS and PAH
medications
- Discontinuation of speciﬁc IS or PAH medications prior
to conception
- Must be a planned
- Medication washout pre-conception
- Discuss assessing extent of ILD, PH, cardiac or renal
involvement in light of safe pregnancy
- Adaptations for child care
- Strategies to manage fatigue

Conception

Care of children
PSYCHOLOGICAL

Advocacy/Education Groups
Local support groups
Online self-management program (see resources)

Important non-pharmacological therapeutic considerations
Exercise as an essential multi-modal disease-modifying medicine
Physical function and activity are key predictors of HRQoL and survival. Available evidence on exercise strongly supports diverse and diffuse beneﬁts of physical activity as a potential cornerstone to
SSc management [88] (Table 15). Exercise reduces inﬂammation and increases circulation (and body
heat), which address essential drivers of SSc symptoms, in addition to enhancing mobility through
improving strength, stiffness, endurance and aerobic capacity. Physical activity is critical for all levels of
ability and for modulating the biochemical impact of depression/anxiety, stress and physical pain e
while improving self-esteem in a disease notorious for diminished self-image. Exercise's muscle and
vascular beneﬁts likely contribute to its beneﬁcial impact on sleep and fatigue [89]. Increasing physical
activity and reduction of a sedentary lifestyle in SSc is crucial to self-management of multiple SScmanifestations, including pulmonary involvement [90]. Patients with SSc desire physician/clinician
counselling and tend to augment their physical activity accordingly. A routine visit should document a
patient's physical activity, counsel on the medicinal effects of exercise and advise that exercise be
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Box 1
Checklist to Support Shared Decision-Making (Courtesy of LA Saketkoo, rights reserved)
Shared Decision-Making Checklist
, Name the patient's items of concern as presented by the patient and if possible which are
highest priority
, Ascertain patient's thoughts on the potential underlying cause/s
, Name the items of concern from the clinical perspective including short and long-term (e.g.
potential progressive damage, associated abrupt complications etc)
, Respond to patient's perceptions of potential cause in support of & clarifying divergence
from patient perceptions. Remain transparent in what is known, unknown, yet to be known and
that which requires literature research by the clinician.
, Name the treatment options available, including any non-pharmacological with particular
attention those suggested by the patient
, Discuss safety, side effects and efficacy (including anticipated onset) of available therapies
and those suggested by the patient.
, Assess patient expectations of treatment
, Set treatment expectations including prognosis, anticipated degree of symptom/impairments resolution, cure versus slowing progression, disease activity versus damage

Table 17
Routine Health Maintenance in SSc. Courtesy of N Sandorﬁ, rights reserved.
Immunization

Age, sex and risk factor
based cancer screening
General
Osteoporosis
Ophthalmology
Dental
Psychological
Laboratory

HPV (ages 16e26), Inﬂuenza (yearly), Hepatitis B, Pneumococcus (at any age with immune
disease), Diphtheria/Tetanus/Pertussis (ages 19e64), Varicella Zoster killed (ages 50 or older),
(*) COVID-19
Gynecological, prostate, gastrointestinal, skin (*)
Higher risk exists around the time of disease onset for those with anti-RNA polymerase III
positivity (with consideration of breast, lung, prostate and tongue cancer)
Hypertension, diabetes cholesterol, sexually transmitted diseases (*)
Women aged 65< or earlier if risk factors exist (special considerations in SSc: malabsorption,
corticosteroid use, prolonged use of proton pump inhibitors) (*)
Special considerations: sicca symptom related complications, hydroxychloroquine associated
toxicity (**)
Routine exam and sicca symptom related complications (***)
Chronic disease related psychological conditions (depression/anxiety) (****)
Tuberculosis, hepatitis C/B screening related to pharmacological therapies

pleasurable, working up to 30-min/day, 5 days weekly; with hand, face and feet exercises to increase
circulation, mobility and anti-inﬂammatory proﬁles regularly reviewed. (See resource list) Further, a
long-term physically active lifestyle improves GI motility and favors enhancement of gut ﬂora [91].
Anticipatory and preventive education
Keys to Patient-Centered Outcomes
Counselling and education (Table 16) based upon models of shared decision-making (SDM) (Box 1)
provide patients with insight into this complex disease as pertains to their circumstances, cultivates
clinician-patient partnership, and increases patient trust, adherence, self-efﬁcacy, and mental health e
all essential to patient outcomes. SDM is an ongoing process requiring time to ensure clinicians understand and address the patient's perceptions, priorities, and self-management activities of their
disease experience. SDM enables effective palliation and protection against disease progression and
complications. Patients with SSc often feel fearful, scared and isolated especially as families, friends,
and many healthcare providers are not familiar with SSc. SDM and provision of resources on selfmanagement strategies and support groups are imperative [92,93].
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Table 18
Patient-centered visit preparations.
Environment
Temperature

Fragrance-free

Supplemental
Oxygen Availability

Wait Times

Nutrition Needs
Hydration
Down time
Visit Times
New Patients
Established Patients
Chart Review

Consolidating Testing
Out-patient

In-patient

Cold can be injurious in SSc
Control clinic temperature exposure via either:
- thermostat adjusted to >72F/22C
- or with blankets for dedicated patient use
Patients should be advised to bring clothing layers to maintain warmth for areas outside of clinic
control
A perfume-free policy maintains a safe environment for patients, family members and clinic
staff:
- fragrance can trigger dyspneic coughing episodes in patients with ILD
- fragrance can impede PFT performance for that patient and other nearby patients or those who
subsequently in the suite
Advisement occurs prior to visit, during scheduling.
Many patients with SSc use supplemental oxygen tanks that hold a limited oxygen supply.
Upon patient arrival, switching their tank to a clinic tank:
- assures sufﬁcient supply for their visit
- preserves supply for the patient's journey home
If this can't be done, patients should be advised of anticipated length of time at the facility for
which they will need to have sufﬁcient supply.
Multiple procedures on a single day can be exhaustive and unanticipated. Helping patients and
families anticipate their needs with the following advisements creates a more comfortable (and
safe) experience:
- Bringing snacks and lunch
- Having water or preferred beverages available
- Reading materials etc. to pass time waiting between tests and visits
Assessment, intervention and counselling in SSc that is sufﬁcient to reduce SSc-related
symptoms and complications requires time.
90 min but can require 3 h, depending on disease extent, complications and initiating
management
45e90 min as even stable patients with SSc requires multi-organ assessment and SSc-speciﬁc
counselling that is beyond a usual visit for most other conditions
SSc management is often time-sensitive and relies upon diagnostic testing and symptom history
trended overtime. New patients often require extensive data organization; while Interval
history is often dense for established patients.
Appropriate chart review requires pre-visit attainment of past and interval medical records.
Documentation of serial data points prior to visit facilitates proactive management, freeing up
clinician attention for meaningful patient-centered discussions.
Real-time interventions and counselling may result in:
- fairly immediate relief of some disabling symptoms
- prevention of disease progression
Chart review is reimbursable in the US, whether on same day or other day.
See resources list for medical record intake template and other clinic support documents.
Consolidating SSc diagnostic testing in as few visits as possible reduces travel burden,
employment impact on patient and family
Past records, pre-visit labs, PFTs, HRCT or echo, ordered prior to scheduled visit, with results
forwarded for clinician review, expedites management during the visit.
Same day SSc-diagnostic testing, prior to clinician visit:
- Common approach at SSc centers: coordinating SSc testing to occur same day, prior to
scheduled visit
An alternate approach for new and established patients at SSc centers in some countries with:
- Approximate 2 day hospital admission
- All routine SSc diagnostic testing and any further testing as indicated by
- Evaluation and teaching by PT/OT
- Management with counselling over one or both days
Patients also visit as out-patients for interim monitoring, repeat testing

35

L.A. Saketkoo, T. Frech, C. Varjú et al.

Best Practice & Research Clinical Rheumatology 35 (2021) 101707

Table 19
Quality healthcare provision sufﬁcient to address the most pressing and essential aspects of SSc care and other complex
multi-system disorders, demands time. Accounting for time usage is foundational for reimbursement or, especially for
countries and provinces where complexity is not accounted for, an advocacy metric for policy revision. Using the 2021 policies
from U.S. Centers for Medicare & Medicaid Services is used as an example below, similar constructs may exist in other countries.
Discrete Care Events

Stipulations for billing
in the US

Chart Review/Pre-visit If occurs same day as
Charting/Post-visit
patient clinic visitt
Charting
If occurs on a day other
than actual clinic visit

Coding
See Clinic Visit Coding
below

Stand alone codes for
non-face-to-face
activity

If occurs as a non-visit
consultation

Tabulate
time-based
visit coding adding
prolonged visit codes
- 99358 for 31e74 min
on non-direct patient care
- 99359 for
each additional
15e30 min i.e. added
for 75e90 min and
again for 104e120
min (maximum)
See below

Complexity-based
No longer requires total
Time-based
time to be 100% ‘faceto-face’
Primary code to which
other codes are added
e.g. prolonged clinician
or staff codes
99441 5e10 min
Time-based for
Patient-initiated
Telephone or internet99442 11e20 min
communication and
queries
based communication
99443 21e30 min
tasks related to query
with patient that is
unrelated to a visit 7
days prior nor leads to
visit in next 24 hours
99415 45e74 min
Clinic Staff Time
Added to clinic visit
99416, each additional 15e30 min
code, for prolonged
services by staff beyond
the typical time
Clinic Visit Breakdown for Time-based Coding
Established Patient
New Patient
99212 10e19 min
99202 15e29 min
99213 20e29 min
99203 30e44 min
99214 30e39 min
99204 45e59 min
99205 60e74 min
99215 40e54 min
Prolonged Visit Coding
99205 or 99215 need to be fulﬁlled then additional codes may be added:
CMS Code: G212
Codes that may be
99354 additional 30e74 min Possible new 2021 codes
Added for each additional 15 min increment AMA Code 99417
obsolete in 2021
99355 for each further
15e30 min increments
Clinic Visit

Routine health maintenance
The medical complexity of SSc often overshadows the importance of routine health maintenance
(RHM). RHM addresses preventive strategies (Table 17) directly related to SSc complications. Vaccinations prevent severe pneumonia and inﬂuenza in ILD/PH. Age-appropriate cancer screening becomes increasingly signiﬁcant given the higher malignancy risk in SSc particularly with antipolymerase III positivity. Screening for cardiovascular disease and OSA may prevent worse outcomes
in those already with cardiopulmonary and circulatory impairment. SSc portends a higher risk of
osteoporosis [94,95] and fractures, and lower vitamin D absorption with chronic PPI use.
Other essential pre-treatment RHM include infectious hepatitis and tuberculosis screening,
consideration of antibiotic prophylaxis, and continued pregnancy planning with females on immunosuppression. As with exercise, keeping RHM as part routine documentation framework will protect
health outcomes in SSc.
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Practical considerations for patient and clinician support
Pre-visit preparations
Patients require time to be heard and time to hear important concepts related to the condition they
are living with. Protecting one's attention and time to address pivotal patient care issues is crucial to
outcomes when caring for people with multiorgan system disease with diverse debilitating manifestations. Attention to patient environment and comfort, anticipatory scheduling to consolidate medical
appointments and employing operational throughputs, e.g., medical record attainment and chart review that support pre-visit data collection, scheduling for realistic appointment durations (with
appropriate billing) facilitate a greater ease of pivotal communication for patient and clinician (Tables
18 and 19 and resources).
Implementing the plan
SSc is a health condition whereby timely treatment of active disease is key to reversibility of
impairment and prevention of permanent damage, whereby even palliative intervention of irreversible
damage can immediately optimize HRQoL, workability, nutrition, mental health, and physical wellbeing and function. Patient education on self-management and engagement with SSc education and
advocacy organizations such as the Scleroderma Foundation, Scleroderma and Raynaud's UK (SRUK),
Federation of European Scleroderma Associations (FESCA), Scleroderma Australia and Scleroderma
India, are central to successful care.
Delays in scheduling diagnostic procedures, therapist and consultant referrals, and treatment
initiation greatly impact patient outcomes. Enlisting an “extended team” of scheduling contacts in
other hospital areas who understand the precarious nature of SSc facilitates teamwork in proactive,
timely and patient-centered scheduling and prior-authorizations.
Prior Authorizations (PAs): Advocacy for streamlining PAs [96] is essential to improve patient survival and outcomes. Further, denials lead to higher insurance company costs [97], as most clinicians
ﬁnally attain authorization [98]. An organized approach can expedite most procedures and medication
authorizations, including an appeal, within 72 h in the US. Correspondence logs to track initiation,
requests for additional information and appeals (see Appendix) streamline response times. In the US,
any licensed health professional (medical assistant, nurse) are considered ‘peers’ in a ‘peer-to-peer’
review; and can obtain approval with increasing efﬁciency overtime.
The Scleroderma Foundation attained Medicare recognition for MMF as a ﬁrst-line therapy in SSc
and SSc-ILD. However important treatments, e.g., rituximab, may not initially receive authorization.
However, insurance peer reviewers will advise that adding “co-existent diagnoses” that satisfy
authorization requirements is reasonable, e.g., “seronegative rheumatoid arthritis” or “lupus,” as long
as manifestations (e.g., inﬂammatory arthritis, ANA positivity) can be supported with documentation
[99] that states “clinical features consistent with___” (co-existent diagnosis). Insurance company requirements for TNF-inhibitors failure before rituximab or tocilizumab, are easily refuted explaining
contraindication in patients at high risk for ﬁbrotic lung disease. Conveying SSc statistics, e.g., 50%
mortality and ensuing disability without appropriate treatment is generally effective.
Proactive Procedure Scheduling: Again, consolidating procedures and clinic appointments enhances overall HRQoL. Appointments can be costly to patients and their families in terms of travel
expenditures and time, work productivity and income loss [100] but also over-medicalizes patients’
lives.
Referral Fulﬁllment: Clinician-to-clinician communication is key to conveying the expeditious nature
of clinical concerns. “Extended teams,” mentioned above, serve to expedite timely scheduling for
therapy and specialist consultations.
Beneﬁts of concurrent care between SSc specialists and general/local specialists
Concurrent care, mutual decision-making, and close communication between a recognized SSccenter and a patients' local rheumatologists, pulmonologists and other specialists, beneﬁt SSc
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patients. SSc remains a complex disease, with professional education disproportionately represented
by industry's easily misinterpreted therapeutic messaging. Patient volume at SSc-centers habituates
attention to the subtleties and complexities of SSc care and therapeutics. SSc centers offer specialty and
experimental treatments, availability of clinical trials, registries, and consultation with specialty PT/OT/
nutritionists.
Future of SSc care
Telehealth offsets the frequency of travel burden for patients and family (e.g., time, logistics,
ﬁnancial, work) with its immediacy possibly expediting initiation of appropriate care. During the
COVID-19 pandemic, supplementing history to target physical exam ﬁndings and guiding patients
in physical exam elements has proven helpful to establish degree of vascular, cutaneous and
musculoskeletal complications. Home spirometry may also support expansion of telehealth visits
[101].
Patient self-management promises to be a critical aspect of SSc health outcomes, including newer
well-being and therapeutic practices that appear to inﬂuence inﬂammation, ﬁbrotic mechanisms,
respiratory function, fatigue, and pain, such as home exercise practices and therapeutic singing
[102e104].

Practice points:
 Serial screening detects potentially lethal complications and is key to decrease disability and
mortality in SSc
 Organ-based documentation optimizes comprehensive assessment, treatment and
counselling.
 Documenting serial patient metrics, such as testing and symptoms, detects ominous early
trends of progressive disease that warrants aggressive intervention, such as dropping PFTs
despite normal values
 Coexistent ILD and PH is common. Co-existent WHO PH groups is also common. Clinical
tools exist to help detect and distinguish pulmonary involvement in SSc
 SSc is very heterogeneous and requires an individualized approach to patient care
 Concurrent care between SSc centers and general/local rheumatologists and pulmonologists
is an increasingly common care model that may enhance patient health outcomes
 Patient-centered and outcome-centered care in SSc demands time. Optimizing clinical
infrastructure and appropriate billing can help protect clinical time with SSc patients
 Optimal health outcomes in SSc demands a multispecialty multidisciplinary approach
 Exercise has multiple-organ based benefits in SSc and may be a disease modifying
intervention

Research agenda
 Investigate the impact of standardized clinical data collection using customizable open
source interfaces like OpenEMR [105] on health outcomes and health disparities in SSc and
other complex multi-organ diseases
 Investigate health economics, health outcomes when clinicians optimize appropriate billing
to protect clinician-patient visits time related to optimized in SSc
 Investigate the potential of early systemic treatment as preventive in the development of
severe gastrointestinal SSc disease (and other manifestations association with disease
duration)
 Characterize the degree and dosage of exercise on SSc local and systemic effects.
 Assess the use of pre-visit intake apps (compared to no app) on patients' clinic visit experiences and health outcomes.
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Summary
SSc is a devastating multisystem disease requiring extensive, thoughtful assessment, organized
documentation and management of multiple organ-related manifestations that can directly impact a
patient's survival and HRQoL. An optimal approach coordinates healthcare services and empowers
access to disease-related education and resources. The future of SSc care depends on effective
communication along with expeditious assessment and treatment with appropriate pharmacological
and non-pharmacological therapeutics. Quality healthcare in SSc is reliant upon sustainable clinical
operations and policy-making that optimize survival and HRQoL in SSc.
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Appendix A
Appendix of Medication Tables
Please note medications marked with ‘^’ are either formally approved by drug agencies for use in SSc
or part of national formularies e.g. MMF in the US.
Raynaud's and Digital Ulcer Medications

Drug Class
Calcium Channel Blocker (CCB)
Angiotensin Receptor Blocker
(ARB)
Angiotensin Converting Enzyme
(ACE) Inhibitors
Alpha Blockers
Nitrates
Phosphodiesterase-5
Inhibitors^
Prostacyclin/prostacyclin
analog^
Endothelial Receptor Blockers^

Drug Names

General Side Effects

Losartan
Valsartan
Captopril, Enalapril,
Quinapril, Ramipril, Lisinopril
Prazosin
Topical Nitroglycerin 2%
Sildenaﬁl
Tadalaﬁl
Epoprostenol
Treprostinil
Iloprost
Bosentan
Ambrisentan
Macitentan

Hypotension, ﬂushing, dizziness, and edema.
Dizziness, diarrhea, hypotension, muscle cramps, and
headache.

Hypotension, dizziness, drowsiness
Rash, headache, facial ﬂushing, hypotension, dry mouth,
tachycardia.
Blurred vision, ﬂushing, headache, hypotension, visual
impairment, tachycardia.
Hypotension, dizziness, muscle cramps, nausea and
vomiting, edema, headache
Hepatoxicity, headache, ﬂushing, edema, fatigue,
hypotension, pruritus, and weight gain.

Topical lidocaine
Botulin Toxin Injections

Avoid getting into eyes or sensitive areas
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Analgesic Medications

Drug Class

Drug names

Concerns for use in SSc

NSAIDS

ibuprofen, naproxen,

Opioids

Hydrocodone
Oxycodone
Tramadol

Anti-convulsants

Gabapentin
Pregabalin

 Esophageal concerns
 Gastritis/gastric bleeding
 Hypertension
 Kidney impairment
 Gastric bleeding
 Fluid Retention
 Cardiac events with long-term use
 Decreased motility in GI tract
 Constipation in general population / may be exaggerated in scleroderma
patients
 Risk of respiratory depression
 Fractionated sleep, impaired sleep
 Pruritus
 Dizziness
 Somnolence
 Swelling

Pharmacological Therapy for Gastrointestinal Manifestations in SSc (Courtesy of Monika Lammi, rights
reserved).

Drug Class
GERD
Proton Pump Inhibitors

Histamine 2
Antagonists
Antiacids

Surface agents

Promotility/LES

Drug Name

Concerns for use/Comments

Pantoprazole*
Omeprazole*
Lansoprazole*
Esomeprazole*
Rabeprazole*
Dexlansoprazole
Famotidine
Ranitadine
Cimetidine
Calcium carbonate
Aluminum hydroxide

*Bioavailability reduced if taken with food
Take 30e60 min before breakfast.
Decreased absorption of: Mg, B12, Fe
Risks (prolonged use): renal insufﬁciency, osteoporosis, atypical
fractures, pneumonia, and dementia.

Gaviscon ± alginate
Sucralfate
Metoclopramide

Domperidone

Buspirone

Baclofen
Gastroparesis
Promotility agents

Metoclopramide

Possible inhibition of cytochrome P450 with possible enhanced
effects of drugs with P450 reliant metabolism
Hyperkalemia, alkalosis and acute or chronic renal injury.
Aluminum retention with neurotoxicity and anemia in renal failure.
Hypophosphatemia.
Can bind to other drugs if taken simultaneously.
Combining with antiacids can amplify these side effects.
May increase gastric motility in patients with systemic sclerosis.
FDA advised against use for more than 3 months
SE: traditive dyskinesia, cardiac arrythmia (monitor with EKG)
Not FDA approved in US. Can be obtained with Investigational New
Drug Application
SE: cardiac arrhythmia
Increases the lower esophageal sphincter pressure, amplitude of
esophageal contractions.
Appears more effective for GERD-related symptoms not esophageal
hypomotility symptoms (dysphagia and chest pain).
Shown to augment lower esophageal sphincter pressure in patients
with GERD. Not studied in patients with SSc.
May increase gastric motility in patients with systemic sclerosis
FDA advised against use for more than 3 months
Risk: traditive dyskinesia, cardiac arrythmia (monitor with EKG)
FDA advised against use for more than 3 months
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(continued )
Drug Class

Drug Name

Concerns for use/Comments

Domperidone

Not FDA approved in US. Can be obtained with Investigational New
Drug Application.
SE: cardiac arrhythmia (monitor with EKG)
Not recommended long term: tachyphylaxis, may cause small
bowel dysmotility.
SE: cardiac arrhythmia (monitor with EKG)
Improves gastric, small bowel and colonic transit.
FDA approved for constipation.
Improves postprandial symptoms and gastric emptying.
More potent acutely than metoclopramide.
Withdrawn from the US market because of cardiac arrhythmia.
SE: Prolongs GI transit, headache, cardiac arrhythmia.
SE: constipation, headache, cardiac arrhythmias
SE: Sedation, tardive dyskinesia
SE: Central, cardiac arrhythmia
As above for GERD and below for dyspepsia.
As below for dyspepsia. May improve early satiety, nausea,
dysmotility manifestations such as gastroparesis, and CIPO.

Erythromycin

Prucalopride
Cisapride

Antiemetics

Neuromodulators

Dyspepsia
Neuromodulators

Ondansetron
Granisetron
Prochlorperazine
Promethazine
Buspirone
Mirtazipine

Buspirone

Improves gastric accommodation and symptoms of dyspepsia, but
decreases gastric emptying of liquids.

Mirtazapine
Improves dyspepsia, early satiety, nausea, emesis, sleep,
depressionSE: weight gain, drowsiness, some risk of mouth dryness
Herbal

FDgard (caraway oil
and I-menthol)
Snall Intestinal Bacterial Overgrowth (SIBO)
Antibiotics
Rifaximin
Metronidazole
Amoxicillin/clavulanic
acid
Norﬂoxacin
Chronic Intestinal pseudo-obstruction
Prokinetics
Metoclopramide
Erythromycin
Prucalopride
Cholinesterase
Pyridostigmine
inhibitor
Somatostatin analog
Octreotide
Constipation
Bulk forming laxatives
Osmotic laxatives
Stimulant laxatives
Guanylate cyclase-C
receptor agonists
Chloride channel
activator
Promotility agent

Psyllium
Methylcellulose
Polyethylene glycol
Bisacodyl
Glycerol
Linaclotide
Plecanatide
Lubiprostone
Prucalopride

Treat for 2 weeks.
High risk of recurrence due to small bowel dysmotility.
Cycle regimens to limit antibiotic resistance.
May consider use of prokinetics, see below.
Antibiotics, e.g. ﬂuoroquinolones may contribute to clostridium
difﬁcile overgrowth
See above.
May also be considered for SIBO.
SE: bradycardia, excessive bronchial secretions, cholinergic crisis
Used in patients who failed to respond to other prokinetic agents.
Inhibits gastric motility.
Patients with gastric dysmotility and visceral hypersensitivity may
not be able to tolerate.
SE: abdominal pain, distention, bloating.

Diarrhea, bloating.
Improves gastric, small bowel and colonic transit.
Diarrhea.
Nausea, diarrhea.
Improves gastric, small bowel and colonic transit.
FDA approved for constipation.
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Systemic treatment/immune suppression/anti-ﬁbrotics.

Drug

Side Effects

Monitoring/Counselling

Common uses

Mycophenolate mofetil
(MMF) mycophenolic
acid^

Diarrhea, increased risk of
infection, headache, fatigue,
leukopenia, thrombocytopenia,
teratogenic

Anti-ﬁbrotic
immunosuppressant
First-line for progressive
ILD
Skin-tightening, Joint
involvement

Cyclophosphamide

Increased risk of infection
Hair loss, GI upset, decreased
appetite, stomatitis,
amenorrhea, interstitial cystitis,
infertility, oligospermia/
azoospermia, Stevens-Johnson
syndrome, increased risk of
bladder cancer
Risk of infection
Infusion reaction common
Very rare, demyelinating
disorders
Risk of Infection
Transaminitis, hepatotoxicity
Very rare, demyelinating
disorders
Rare risk of GI perforation
Hyperlipidemia
Headache, fatigue, renal
dysfunction, transient ischemic
episodes, cerebrovascular
event, urticaria, ﬂushing,
hypertension, aseptic
meningitis
Extreme immunosuppression
High risk of infection and sepsis
Heart failure, arrhythmia
Nausea, diarrhea,
hepatotoxicity, stomatitis,
alopecia, myelosuppression,
teratogenic
Medication-induced
pneumonitis, rare
Increased risk of infection
GI upset, myalgia, leukopenia,
thrombocytopenia, risk of
infection, hepatotoxicity
Scleroderma Renal Crisis
Amongst many other
potentially detrimental side
effects
Hepatotoxicity
Nausea, Diarrhea,
Hypertension, Rash, Headache,
Abdominal pain, Alopecia;
Peripheral neuropathy
Nausea, Diarrhea, Headache,
Photosensitivity,
Myelosuppression

CBC, serum electrolytes
especially with ongoing
diarrhea, drug interactions;
REMS (pregnancy)
If side effects occur, decrease
dose to side effect free level,
and keep at this dose for longer
period before increasing again.
Use of contraception
CBC, urinalysis (monthly if on IV
therapy)

Rituximab

Tocilizumab^

Intravenous
Immunoglobulin G

Hematopoietic Stem
Cell Transplantation
Methotrexate

Azathioprine

Glucocorticoids

Leﬂunomide

Sulfasalazine

Serum lipids
CBC
Transaminases

Progressive ILD
Progressive skin-tightening

Progressive skin-tightness
Progressive ILD
Joint involvement, possibly
PH
Skin-tightness
Joint involvement
Slowing down progressive
ILD
Possibly PH
Progressive SSc

Per protocol

Progressive SSc prior to
signiﬁcant organ damage

CBC, Serum creatinine,
Transaminases,
Concomitant use of folic acid
Avoidance of alcohol
Use of contraception

Joint involvement

Signs of bleeding, jaundice,
change in color of stool; TPMT
deﬁciency, drug interactions
Opportunities to lower dose or
discontinue

Joint involvement

CBC and transaminases, signs of
infection
Avoid alcohol, use of
contraception

Joint involvement

CBC
GI distress, SPF use

Joint involvement
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(continued )
Drug

Side Effects

Monitoring/Counselling

Common uses

Hydroxy-chloroquine

Nausea, Diarrhea, Headache,
vision changes
Rarely myopathy
Rarely myelosuppression

Joint involvement

Anti-Fibrotic e.g.
nintedanib^,
pirfenidone

Gastrointestinal distress,
hepatotoxicity, fatigue, swelling

Baseline eye exam
Screening according to
published protocols
Visual changes at night or
peripheral
Transaminase levels
Electrolytes with vomiting or
diarrhea

Slowing down lung
progression. Uncertain
regarding whether these
have systemic effects, thus
far there has been no
demonstrated
improvement on skin, joint,
or quality of life.

Appendix of Clinician and Patient Resources
Clinical skills resources
Functional Index-2: https://www.youtube.com/watch?v¼qw4XvWKQErU.
Manual Muscle Test 8 (MMT-8): https://www.niehs.nih.gov/research/resources/assets/docs/
mmt8_grading_and_testing_procedures_for_the_abbreviated_8_muscle_groups_508.pdf.
Modiﬁed Rodnan Skin Score: https://www.youtube.com/watch?v¼Bl3EX_2PaUc.
Timed Up and Go Test: https://youtu.be/auqAb_AWM1U.
TImed sit to stand test: https://www.youtube.com/watch?v¼puJhQXUlbdA.
30-s Sit to Stand Test: https://www.youtube.com/watch?v¼PzCTwkJVhWg.
DETECT Algorithm for PH Screening: https://www.suspectpahctd.com/DETECT/ NOTICE: this tool
does not replace clinical judgement. Only right heart catheterization is currently able to determine
presence of pulmonary hypertension.
Examples of Clinic Operations Documents
Medical Records Intake Form for Scheduling New Patients: https://www.dropbox.com/s/
wapuv8p8dkoz2n3/PATIENT%20SCHEDULING%20INTERVIEW.docx?dl¼0.
New Patient Questionnaire:
https://www.dropbox.com/s/jynfaq5ax3cyo8a/SSc%20Patient%20Intake%20Form.docx?dl¼0.
Infusion Order Record:
https://www.dropbox.com/s/v1vkwiegpjhead4/INFUSION%20ORDER%20RECORD.docx?dl¼0.
Oral Medication Authorization Record: https://www.dropbox.com/s/algr06i6upndtmf/RECORD%
20ORAL%20MEDS%20PRIOR%20AUTH.docx?dl¼0.
Patient Questionnaires:
StopBang questionnaire online calculator: http://stopbang.ca/osa/screening.php
Epworth Sleepiness Scale
https://www.thecalculator.co/health/Epworth-Sleepiness-Scale-Calculator-905.html
http://epworthsleepinessscale.com/
Scleroderma Health Assessment Questionnaire: https://www.dropbox.com/s/gd9847e9bw82101/
SHAQ%20-%20SF36%20-%20Cochin%20Hand%20Function.doc?dl¼0.
SF-36 form: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html
https://www.rand36calculator.com/
Cochin Hand Function Questionnaire: https://www.dropbox.com/s/gd9847e9bw82101/SHAQ%
20-%20SF36%20-%20Cochin%20Hand%20Function.doc?dl¼0.
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Giessen GI Form: https://www.dropbox.com/s/o2i68d7f4ojvu4h/Giessen%20Gastrointestinal%
20Questionnaire%20for%20Scleroderma.doc?dl¼0.
SSc-GIT:
https://www.dropbox.com/s/yi5wzl3yezgmqn7/GIT%20Questionnaire%20-%20The%
20Actual%20Survey.doc?dl¼0.
Patient Speciﬁc Functional Scale (PSFS) User Manual: https://www.physio-pedia.com/Patient_
Speciﬁc_Functional_Scale.
Patient and physician education and advocacy resources
Scleroderma Foundation: www.scleroderma.org/
FESCA: www.fesca-scleroderma.eu/wordpress/
Scleroderma Australia: https://www.sclerodermaaustralia.com.au/
Scleroderma & Raynaud's UK: https://www.sruk.co.uk/scleroderma/
Scleroderma societies of Canada and ontario: www.scleroderma.ca/,
sclerodermaontario.ca/, https://sclerodermie.ca/en/
Pulmonary ﬁbrosis foundation: https://www.pulmonaryﬁbrosis.org/
Pulmonary hypertension association: https://phassociation.org/
Renal crisis card: https://ard.bmj.com/content/74/Suppl_2/1136.1

https://www.

Educational resources for patients
Oxygen use (for patients in the U.S.): https://www.dropbox.com/s/3d8wyikb8204ira/What%
20Patients%20Should%20Know%20About%20OXYGEN%20THERAPY%20-%208%20-2-2017.pdf?dl¼0
Patient information on medications: www.rheuminfo.com/
Janet Poole Hands/Face Instructional Links: https://www.youtube.com/watch?v¼1F02FxdOgwI.
https://www.youtube.com/watch?v¼8MztM3zItik
https://www.youtube.com/watch?v¼YwWP7mgcYhU
Stretching exercises for the hand and face. The Scleroderma Foundation, http://www.
scleroderma.org/site/DocServer/Form_16c_low_res.pdf?docID¼19809&AddInterest¼1281.
Taking Charge of Systemic Sclerosis (TOSS): an internet program for systemic sclerosis. https://
www.selfmanagescleroderma.com/
Living Well: Heart, Lung, Muscle & Mind: A collection of videos dedicated to yoga rehab and dance
rehab for heart, lung, muscle and autoimmune conditions
https://www.youtube.com/channel/UCRgvkbyzep-Q3LGBiAksQZw/videos.
3-3-1 exercise tutorial https://www.youtube.com/watch?v¼zsBRxmkzAnM&t¼2s
Move Towards Health: UMC CPHC Instructional Booklet on Safe Home-based Dance Practice
https://doi.org/10.13140/RG.2.2.25576.49927.
Sleep Booklet: https://www.dropbox.com/s/0axd782mi818smc/SF%20Arizona%20Conference%20%20SLEEP%20-%20DOUBLE%20Booklet.docx?dl¼0.
Mindfulness booklet: https://www.dropbox.com/s/mrpl33zxjsk20br/SF%20Arizona%20Conference%
20-%20RESTORE%20YOURSELF-%20DOUBLE%20Booklet.docx?dl¼0
Mindfulness in scleroderma videos: https://www.youtube.com/watch?v¼pNK9RP4Abyw
https://www.youtube.com/watch?v¼lmQKOCDJ19Y
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